

BMJ Open

Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-015843
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2017
Complete List of Authors:	Mansfield, Avril; Toronto Rehabilitation Institute, Brooks, Dina; University of Toronto, Physical Therapy Tang, Ada; McMaster University, School of Rehabilitation Science Taylor, Denise; St Joseph's Care Group Inness, Elizabeth; Toronto Rehabilitation Institute, Balance Mobility and Falls Clinic Kiss, Alex; Sunnybrooke Research Institute, Department of Research Design and Biostatistics Middleton, Laura; University of Waterloo, Kinesiology; Sunnybrook Research Institute, Heart and Stroke Foundation Centre for Stroke Recovery Biasin, Louis; Toronto Rehabilitation Institute, Balance Mobility and Falls Clinic Fleck, Rebecca; Hamilton Health Sciences, Regional Rehabilitation Program French, Esmé; Northwestern Ontario Regional Stroke Network LeBlanc, Kathryn; Hamilton Health Sciences, Regional Rehabilitation Program Aqui, Anthony; Toronto Rehabilitation Institute Danells, Cynthia; Toronto Rehabilitation Institute
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Neurology
Keywords:	Stroke < NEUROLOGY, Exercise, Behaviour change, Physical activity, Physiotherapy

SCHOLARONE™
Manuscripts

1. ADMINISTRATIVE INFORMATION

Title: Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial

Authors: Avril Mansfield,^{1,3} Dina Brooks,^{1,3,4} Ada Tang,⁵ Denise Taylor,^{6,7} Elizabeth L Inness,^{1,3} Alex Kiss,² Laura Middleton,^{1,8} Louis Biasin,^{1,3} Rebecca Fleck,⁹ Esmé French,¹⁰ Kathryn LeBlanc,⁹ Anthony Aqui,¹ Cynthia Danells^{1,3}

Corresponding author: Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca

Affiliations: ¹Toronto Rehabilitation Institute, Toronto, ON, Canada; ²Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada; ³Department of Physical Therapy, University of Toronto, Toronto, ON, Canada; ⁴West Park Healthcare Centre, Toronto, ON, Canada; ⁵School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada; ⁶St Joseph's Care Group, Thunder Bay, ON, Canada; ⁷Northern Ontario School of Medicine, West Campus, Thunder Bay, ON, Canada; ⁸Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada; ⁹Regional Rehabilitation Program, Hamilton Health Sciences, Hamilton, ON, Canada; ¹⁰Northwestern Ontario Regional Stroke Network, Thunder Bay, ON, Canada

Key words: Stroke; Exercise; Physical Activity; Behaviour Change; Physiotherapy

Word count: 6,137

Protocol version date: 4 January 2017; Original

Funding: This study is supported by the Canadian Institutes of Health Research (PJT-148906). AM holds a New Investigator Award from the Canadian Institutes of Health Research (MSH-141983). DB holds a Canada Research Chair. AT is supported by a personnel award from the Heart and Stroke Foundation, Ontario Provincial Office (CS I 7468). These funding sources had no role in the design of

1
2 25 this study and will not have any role during its execution, analyses, interpretation of the data, or
3
4 26 decision to submit results.
5

6 27 **Roles:** AM conceived of the study, is the grant holder, and drafted the manuscript. AM, DB, AT, and
7
8 28 DT will lead implementation of the study at each site, with assistance from ELI, LB, RF, EF, KL, and
9
10 29 CD. ELI, LB, and CD developed the intervention. AK provided statistical expertise and will conduct
11
12 30 the primary statistical analysis. AM, DB, AT, DT, ELI, AK, LM, LB, RF, EF, KL, AA, and CD
13
14 31 contributed to refining the study protocol and approved the final manuscript.
15
16
17
18 32

2. WHO DATASET

1. **Trial registration:** clinicaltrials.gov, NCT02951338
2. **Date of registration:** 31 October 2016
3. **Secondary identification numbers:** Not applicable
4. **Sources of monetary or material support:** This study is supported by the Canadian Institutes of Health Research (PJT-148906). AM holds a New Investigator Award from the Canadian Institutes of Health Research (MSH-141983). DB holds a Canada Research Chair. AT is supported by a personnel award from the Heart and Stroke Foundation, Ontario Provincial Office (CS I 7468). The views expressed are not necessarily those of the funders.
5. **Primary sponsor:** Avril Mansfield
6. **Secondary sponsors:** Dina Brooks, Ada Tang, Denise Taylor
7. **Contact for public queries:** Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca
8. **Contact for scientific queries:** Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca
9. **Public title:** Promoting Optimal Physical Exercise for Life (PROPEL) in people with stroke
10. **Scientific title:** Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial
11. **Countries of recruitment:** Canada
12. **Interventions:** Group aerobic exercise only (Active Comparator): Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal or maximal aerobic capacity test, and a 3-5 minute 'cool-down' of low-intensity exercise. The

1
2 57 choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper,
3
4 58 cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor
5
6 59 recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of
7
8
9 60 perceived exertion, workload, and duration of training will be documented for each session.
10
11 61 These data will be reviewed by the physiotherapist with appropriate progression of the intensity
12
13 62 and/or duration of exercise as necessary. Participants may receive general advice to keep
14
15 63 physically active after discharge, and may receive an individualized home exercise program, as
16
17
18 64 is currently routine care at all sites. PROPEL program (experimental): The PROPEL program
19
20 65 involves both group aerobic exercise (as described above) and group discussion aimed at
21
22 66 enabling participation in exercise after discharge. Components of the PROPEL program were
23
24
25 67 developed according to the Transtheoretical Model of health behaviour change and Social
26
27 68 Cognitive Theory. In addition to group exercise participants will attend 1-hour small group
28
29 69 discussion sessions once weekly to learn self-management skills for exercise in preparation for
30
31
32 70 discharge from rehabilitation. These discussions include: identifying and solving problems
33
34 71 around barriers to exercise; understanding personal and general benefits of exercise; exploring
35
36 72 appropriate community resources for exercise; and finding individualized and realistic strategies
37
38
39 73 for incorporating exercise in a regular routine. Participants will become comfortable with
40
41 74 progressing their exercise and will set short- and long-term goals for engaging in physical
42
43 75 activity and exercise after discharge.

- 45 76 **13. Key inclusion and exclusion criteria:** Inclusion criteria: Adults with stroke who are referred to
47
48 77 the group aerobic exercise or PROPEL programs as part of their stroke rehabilitation. Exclusion
49
50 78 criteria: Language or communication barrier that prevents completion of questionnaires (e.g.,
51
52 79 severe receptive or global aphasia or non-English speaking); cognitive impairment that would
53
54
55 80 prevent participation in unsupervised exercise; attend less than 50% of group aerobic

1
2 81 exercise/PROPEL sessions; and/or attend less than 4 of the 6 group discussion sessions (for
3
4 82 individuals referred to the PROPEL program).
5

6 83 14. **Study type:** Interventional stepped-wedge cluster randomized trial.
7

8
9 84 15. **Date of first enrolment:** February 2017 (anticipated)
10

11 85 16. **Target sample size:** 192
12

13 86 17. **Recruitment status:** Pending: participants are not yet being recruited or enrolled at any site.
14

15
16 87 18. **Primary outcomes:** Number of patients who meet recommended intensity, frequency, and
17
18 88 duration of physical activity; that is, at least 150 minutes per week of moderate-to-vigorous
19
20 89 intensity exercise. Physical activity will be assessed using a step counter, heart rate monitor,
21
22 90 and questionnaire for 7 continuous days at 1-month, 4-months, and 6-months post-discharge.
23
24

25 91 19. **Secondary outcomes:** Short Self-efficacy for Exercise Scale; Short Outcome Expectation for
26
27 92 Exercise Scale; and Barriers to Being Active Quiz
28
29

30 93
31

32 94
33

34 95
35

36 96
37

38 97
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. ABSTRACT

Introduction: Physical exercise after stroke is essential for improving recovery and general health, and reducing future stroke risk. However, people with stroke are not sufficiently active upon return to the community after rehabilitation. We developed the Promoting Optimal Physical Exercise for Life (PROPEL) program, which combines exercise with self-management strategies within rehabilitation to promote ongoing physical activity in the community after rehabilitation. This study aims to evaluate the effect of PROPEL on long-term participation in exercise after discharge from stroke rehabilitation. We hypothesize that individuals who complete PROPEL will be more likely to meet recommended frequency, duration, and intensity of exercise compared to individuals who do not complete the program up to 6-months post-discharge from stroke rehabilitation.

Methods and analysis: Individuals undergoing outpatient stroke rehabilitation at one of 6 hospitals will be recruited (target n=192 total). A stepped wedge design will be employed; i.e., the PROPEL intervention (group exercise plus self-management) will be ‘rolled out’ to each site at a random time within the study period. Prior to roll-out of the PROPEL intervention, sites will complete the control intervention (group aerobic exercise only). Participation in physical activity for 6-months post-discharge will be measured via activity and heart-rate monitors, and standardized physical activity questionnaire. Adherence to exercise guidelines will be evaluated by: 1) number of ‘active minutes’ per week (from the activity monitor); 2) amount of time per week when heart rate is within a target range (i.e., 55-80% of age-predicted maximum); and 3) amount of time per week completing ‘moderate’ or ‘strenuous’ physical activities (from the questionnaire).

Ethics and dissemination: Research ethics approval has been received from two of the six sites. Results will be disseminated directly to study participants at the end of the trial, and to other stakeholders via publication in a peer-reviewed journal.

4. ARTICLE SUMMARY

- This multi-centre trial will determine if an exercise and self-management intervention can increase participation in physical activity after stroke rehabilitation.
- The novel ‘stepped wedge’ trial design is suitable given the group-based delivery of the intervention and relatively small number of sites involved.
- Participation in physical activity will be determined with three methods: self-report (activity questionnaire), daily heart rate monitoring, and daily activity monitoring.
- The trial is single-blinded (participants cannot be blinded to intervention allocation), which potentially introduces a source of bias.

5. INTRODUCTION

5.1 Background and rationale

People often have low aerobic capacity after stroke,^{1 2} which can limit the stroke survivors' ability to complete activities of daily living.^{1 3 4} Aerobic exercise is beneficial post-stroke for improving aerobic capacity,⁵⁻⁷ maintaining or promoting recovery⁸ and for general health, including reducing risk of another stroke or other cardiovascular events.⁹ Indeed, aerobic exercise is beneficial and feasible even early after stroke and during routine rehabilitation^{6 10} However, due to the brief length of stay in stroke rehabilitation (4-6 weeks), ongoing self-directed physical activity post-discharge is necessary to maintain these benefits.

People with stroke do not maintain adequate levels of long-term exercise. Community-living people with stroke walk, on average, 70 to 5800 steps/day,¹¹ which is less than the 6000 steps/day recommended for people with physical disabilities.¹² Data from heart rate monitors revealed that, even when individuals with stroke were active, the activity was not of sufficient intensity for aerobic benefit.¹³ This chronic inactivity means that gains in aerobic fitness made during rehabilitation will be lost post-discharge.¹⁴

There is a need to establish strategies to promote long-term uptake of exercise after stroke.¹⁵ Most studies aiming to increase self-directed exercise post-stroke have been implemented in the community after formal rehabilitation is complete.^{16 17} While some community-based programs have reported increased physical activity after the program,¹⁸⁻²⁰ many people have difficulty accessing community programs¹⁶ and consequently attendance can be low.²¹ The early recovery period during rehabilitation may be an optimal time to not only deliver fitness programming to increase exercise capacity, but also to shape long-term self-directed exercise behaviour.¹⁴ To our knowledge only one group has studied such a program during stroke rehabilitation.²² This study found that 67% of those who completed the intervention met exercise recommendations, compared to 55% in the control group.

1
2 156 However, this study was limited by a non-randomized design, high rates of withdrawal in the
3
4 157 intervention group compared to the control group (28% versus 12%), and low rates of compliance with
5
6 158 the intervention (<67%). Furthermore, this study included individuals receiving rehabilitation for
7
8
9 159 various conditions and was not focused solely on people with stroke, who have unique challenges to
10
11 160 participating in exercise.²³

13 161 We developed Promoting Optimal Physical Exercise for Life (PROPEL) – a combined group
14
15
16 162 exercise and self-management program that aims to promote long-term engagement in exercise and
17
18 163 physical activity after stroke. Our pilot non-randomized study suggests that those who complete
19
20 164 PROPEL are more physically active after discharge from rehabilitation than those who do not.²⁴
21
22
23 165

25 166 **5.2 Objectives**

27 167 The primary aim of this study is to evaluate the effect of PROPEL delivered during stroke
28
29
30 168 rehabilitation on participation in self-directed exercise after rehabilitation. Our secondary aims are to
31
32 169 evaluate the effect of PROPEL on self-efficacy and outcome expectations for exercise, and barriers to
33
34 170 exercise. We hypothesize that, compared to those who complete group aerobic exercise only, those
35
36 171 who complete PROPEL will: 1) be more likely to meet the recommended intensity and duration of self-
37
38
39 172 directed physical activity in the community (i.e., ≥ 150 mins/week of moderate intensity exercise²⁵); and
40
41 173 2) report higher self-efficacy and outcome expectations for exercise, and fewer barriers to community
42
43 174 activity.
44
45
46 175

48 176 **5.3 Trial design**

50 177 This study involves a single-blind (assessor blinded), continuous recruitment short exposure, stepped-
51
52
53 178 wedge cluster randomized controlled superiority trial (SWT).²⁶ Six sites will be involved in the study;
54
55 179 at a randomly-determined time within the study period (Figure 1), each site will transition from the
56
57
58
59
60

1
2 180 control intervention (group aerobic exercise only; GAE) to the experimental intervention (PROPEL).
3
4 181 New participants will be recruited continuously throughout the study period and will either complete
5
6 182 the GAE or PROPEL intervention, depending on which program that site is administering at the time at
7
8
9 183 which they are admitted to rehabilitation.

10
11 184 The group format is essential to PROPEL (see below). In our pilot study²⁴ there was often a
12
13 185 delay to start the group in order to have ≥ 3 people enrolled. Therefore, a study design whereby
14
15 186 individual participants are randomly allocated to either GAE or PROPEL would be problematic as
16
17
18 187 there would be even greater delays in starting the groups since twice as many people would be required
19
20 188 to be enrolled in order to run concurrent groups. Likewise, a traditional cluster randomized controlled
21
22
23 189 trial, where sites are randomly assigned to either complete GAE or PROPEL, would not be ideal due to
24
25 190 the relatively low number of sites (6), and thus, reduced statistical power.²⁷ Therefore, the SWT is a
26
27 191 pragmatic trial design that is suitable for evaluating interventions that are implemented routinely at the
28
29
30 192 level of cluster.^{26 27} It balances the need for robust evaluation with logistic constraints in program
31
32 193 evaluation, particularly in cases of inter-site variability.²⁸ Indeed, previous authors have argued that
33
34 194 well-designed and executed SWTs can be as rigorous as traditional cluster randomized trials.²⁶

35 36 37 195 38 39 196 **6. METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES**

40 41 197 **6.1 Study setting**

42
43 198 Participants will be recruited from one of 6 rehabilitation hospitals in Ontario: 1) Hamilton Health
44
45
46 199 Sciences, Hamilton, Ontario; 2) St. Joseph's Care Group, Thunder Bay, Ontario; 3) Sunnybrook Health
47
48 200 Sciences Centre – St. John's Rehab, Toronto, Ontario; 4) Toronto Rehabilitation Institute – Rumsey
49
50 201 Centre, Toronto, Ontario; 5) Toronto Rehabilitation Institute – University Centre, Toronto, Ontario;
51
52
53 202 and 6) West Park Healthcare Centre, Toronto, Ontario. Each site will be staffed by a research assistant

(RA) and a physiotherapist (PT). The RA will be responsible for recruiting participants and collecting data. The PT will administer the interventions.

6.2 Eligibility criteria

Individuals who complete either GAE or PROPEL as part of routine care at one of the 6 sites will be invited to participate in the study. To be eligible for referral to GAE or PROPEL, patients must be admitted to the facility for rehabilitation after a diagnosed stroke, and must be able to understand instructions. Patients will be excluded from GAE or PROPEL if they have conditions that limit their ability to exercise, including uncontrolled hypertension, uncontrolled diabetes, other cardiovascular morbidity that limits exercise tolerance (e.g., heart failure, abnormal blood pressure responses or ST-segment depression >2mm, symptomatic aortic stenosis, or complex arrhythmias), unstable angina, orthostatic blood pressure decrease of >20mmHg, or musculoskeletal impairments or pain. Additionally, participants will be withdrawn from GAE or PROPEL if significant cardiovascular abnormalities are observed during the sub-maximal exercise test. We have used these criteria to successfully enrol patients with stroke in aerobic exercise during in-patient rehabilitation with no serious adverse events.¹⁰ Referral to the group will be made by the patients' primary treating physiotherapists, who will document the patients' verbal consent for treatment, as is usual practice.

Participants will be considered for inclusion in the study if they are referred to the GAE or PROPEL program as part of their stroke rehabilitation. Participants will be excluded from the study if:

- They have a language or communication barrier that prevents completion of questionnaires (e.g., severe receptive or global aphasia or non-English speaking);
- They have cognitive impairment that would prevent participation in unsupervised exercise;
- They attend less than 50% of GAE/PROPEL sessions; and/or

- They attend less than 4 of the 6 group discussion sessions (for individuals enrolled in the PROPEL program).

Communication and cognitive capacity to participate in the study will be determined via consultation with participants' healthcare team.

6.3 Interventions

The interventions will be implemented as part of routine care at all sites according to the schedule outlined in Figure 1 (e.g., Site B is expected to implement GAE in mid-February 2017, and PROPEL in around mid-May 2017). The interventions will supplement, rather than replace, current practice; that is, patients will still complete their regularly-scheduled physiotherapy, occupational therapy, and speech and language pathology sessions, as required. However, for patients who are enrolled in the GAE or PROPEL interventions, physiotherapists might choose not to complete individualized aerobic exercise during patients' regularly scheduled physiotherapy sessions as this will be completed as part of GAE/PROPEL, and to spend this time instead focusing on other rehabilitation goals (e.g., balance or gait retraining).

Both interventions involve supervised, individualized, group aerobic exercise up to 3 days/week for 6 weeks informed by a sub-maximal or maximal aerobic capacity test. Patients will be referred by their treating physiotherapist. The interventions will be delivered in a 'closed group' format. That is, participants referred to the program will be placed on a waiting list until there are a sufficient number of participants to form a group (≥ 3), and all participants in the group will start and end the program at the same time. The closed-group format is essential for the PROPEL phase as the education and group discussion topics will be presented in a specific order. An open-group format could be used for GAE; however, this would result in participants in the GAE phase being recruited to the study, on average, sooner post-stroke than those in the PROPEL phase.²⁴ Therefore, using a closed-group format for both

1
2 251 phases will help to ensure that the mean time post-stroke at study enrolment does not differ between the
3
4 252 two phases of intervention. Prior to starting the group, participants may complete individualized or
5
6 253 open-group aerobic exercise as part of their regular in- or out-patient rehabilitation.
7
8

9 254 10 11 255 *6.3.1 Control intervention – GAE*

12
13 256 The control intervention will involve group aerobic exercise only (GAE). The intensity and duration of
14
15 257 exercise will be determined from the results of a sub-maximal or maximal aerobic capacity test
16
17 258 conducted prior to entry into the program. The choice of exercise modality for the submaximal test and
18
19 259 for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed
20
21 260 based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Group
22
23 261 exercise will be supervised by the PT. A typical exercise session will involve a 3-5 minute 'warm-up',
24
25 262 20-30 minutes of aerobic exercise at a target heart rate determined from the sub-maximal test, and a 3-5
26
27 263 minute 'cool-down' of low-intensity exercise. Heart rate, blood pressure, rate of perceived exertion,
28
29 264 workload, and duration of training will be documented for each session. These data will be reviewed by
30
31 265 the PT with appropriate progression of the intensity and/or duration of exercise as necessary.
32
33
34 266

35
36 267 Patients in the GAE program may receive general advice to keep physically active after
37
38 268 discharge, and may receive an individualized home exercise program, as is currently routine care at all
39
40 269 sites.
41
42

43 270 44 45 271 *6.3.2 Experimental intervention – PROPEL*

46
47 272 The PROPEL program,²⁴ involves both group aerobic exercise and group discussion aimed at enabling
48
49 273 participation in exercise after discharge. Components of the PROPEL program were developed
50
51 274 according to the Transtheoretical Model of health behaviour change²⁹ and Social Cognitive Theory.³⁰
52
53 275 Participants will complete group exercise up to 3 days/week (described above for GAE). Additionally,
54
55
56
57
58
59
60

1
2 275 participants will also attend 1-hour small group discussion sessions once weekly to learn self-
3
4 276 management skills for exercise in preparation for discharge from rehabilitation. These group sessions
5
6 277 include discussions to: identify and problem-solve barriers to exercise; understand personal and general
7
8
9 278 benefits of exercise; explore appropriate community resources for exercise; and find individualized and
10
11 279 realistic strategies for incorporating exercise in a regular routine. The group format helps to promote
12
13 280 vicarious experiences. To promote independence, patients will learn how to monitor their own heart
14
15 281 rate and rate of perceived exertion. Patients will also become comfortable with progressing their
16
17
18 282 aerobic exercise and will set short- and long-term exercise goals. Access to a health care professional
19
20 283 (PT) leading the group can increase an individual's belief about personal skill,³¹ and support in teaching
21
22 284 stroke survivors how to exercise independently, promoting feelings of safety and confidence.^{32 33}
23
24
25 285

27 286 **6.4 Outcomes**

29 287 *6.4.1 Primary outcomes – physical activity*

31
32 288 Physical activity will be assessed using a step counter and heart rate monitor for 7 continuous days, as
33
34 289 well as a physical activity questionnaire at three time points: 1) one month, 2) four months, and 3) six
35
36 290 months post-intervention (Figure 2). Because of the limitations of relying on a single method of data
37
38 291 collection for physical activity data, combining data from these three sources is recommended.^{13 23 24 34}
39
40
41 292 Participants will be supplied with a commercial wrist-worn step counter and heart rate monitor (FitBit
42
43 293 Charge HR). Our pilot data suggest that this device provides reasonably accurate measures of walking
44
45 294 activity and heart rate among individuals with stroke (unpublished data). Individuals who typically use
46
47
48 295 a rollator for ambulation may also be provided with an activity monitor to be worn at the ankle (FitBit
49
50 296 One), which would be more accurate for measuring walking activity than a wrist-worn device for these
51
52 297 individuals.³⁵ The devices will be configured to not provide participants with information regarding
53
54
55 298 step counts and heart rate. The devices will be mailed to participants with a postage-paid return
56
57
58
59
60

1
2 299 envelope. Participants will be instructed to wear the device at all times (except when bathing) for 7
3
4 300 days continuously.

6 301 The Physical Activity Scale for Individuals with Physical Disabilities (PASIPD)³⁶ will be
7
8
9 302 conducted by telephone with a blinded RA at the end of the 7-day monitoring period. The PASIPD is a
10
11 303 13-item questionnaire in which participants are asked to indicate the frequency and duration of
12
13 304 recreational, household and occupational physical activities completed in the previous 7 days. The
14
15
16 305 PASID has been validated within a group of individuals with various physical disabilities, including
17
18 306 individuals with stroke, showing good test-retest reliability ($\rho=0.77$) and criterion validity when
19
20
21 307 compared to accelerometer-based activity monitoring ($\rho=0.30$).³⁷

23 308 We will use the step activity, heart rate, and questionnaire data to determine if participants meet
24
25 309 the recommended intensity and duration of physical activity in the community; that is, at least 150
26
27
28 310 minutes per week of moderate-vigorous intensity exercise.²⁵ Participants will be deemed to meet the
29
30 311 recommendations within a given week if they meet at least two of three criteria: 1) record at least 150
31
32 312 'active minutes' (from the step activity monitor); 2) record at least 150 minutes of heart rate between
33
34 313 55-80% of age-predicted maximum;⁹ and/or 3) report at least 150 minutes of moderate and/or vigorous
35
36
37 314 intensity activity on the PASIPD.

41 316 *6.4.2 Secondary outcomes - self-efficacy and outcome expectations for exercise, and barriers to activity*

43 317 Exercise self-efficacy will be assessed using the Short Self-Efficacy for Exercise (SSEE) scale.³⁸ The
44
45
46 318 SSEE is a four-item questionnaire where participants are required to rate their confidence exercising
47
48 319 through pain and fatigue, and when alone and depressed on a five-point scale. The Short Outcome
49
50
51 320 Expectation for Exercise (SOEE) scale³⁸ will be used to assess beliefs and attitudes related to exercise.
52
53 321 The SOEE is a five-item questionnaire where participants are asked to rate their beliefs regarding the
54
55 322 benefits of exercise on a five-point scale. The SSEE and SOEE will be assessed at enrolment into the

1
2 323 study. The SSEE and SOEE have been shown to be valid and reliable among individuals with chronic
3
4 324 stroke.³⁸
5

6 325 Perceived barriers to physical activity will be assessed 1-month post-intervention with the
7
8
9 326 Barriers to Being Active Quiz (BBAQ).^{23 39} The BBAQ has previous been used to evaluate barriers to
10
11 327 exercise among individuals with stroke.²³ The BBAQ is a 21-item scale where individuals are required
12
13 328 to indicate how likely they are to make specific statements regarding barriers to exercise, for example
14
15
16 329 “I’m getting older so exercise can be risky”.³⁹ Items on seven categories of barriers are included in the
17
18 330 questionnaire: lack of time, social influence, lack of energy, lack of willpower, fear of injury, lack of
19
20 331 skill, and lack of resources. Each individual item is scored from 0-3 and scores for each barrier
21
22 332 category are the sum of the scores for the three items in that category. Participants are considered to
23
24
25 333 have a ‘significant’ barrier to being active if the score for a category is 5 or higher.²³ The average
26
27 334 number of significant barriers per participant will be calculated.
28
29
30 335

31 336 *6.4.3 Cohort descriptors*

32 337 The following information will be obtained from chart review in order to characterize individuals who
33
34 338 participate in the study: age, sex, time post-stroke (at enrolment into the study), lesion location,
35
36
37 339 mobility status, and medical conditions/history. The National Institutes of Health Stroke Scale (NIH-
38
39 340 SS),⁴⁰ the Chedoke-McMaster Stroke Assessment (CMSA)⁴¹ foot and leg scores, and the Montreal
40
41 341 Cognitive Assessment⁴² will be administered at enrolment into the study by the RA or study PT;
42
43
44 342 however, if these measures were conducted as part of clinical care within 1-week of study enrolment,
45
46
47 343 the scores will be extracted from the hospital charts to minimize participant burden. The NIH-SS is an
48
49
50 344 11-item scale that provides a gross measure of the effects and severity of stroke. The NIH-SS has good
51
52 345 intra-rater (ICCs=0.93) and inter-rater (ICCs=0.95) reliability.⁴³ The CMSA assigns a score according
53
54
55 346 to the level of motor recovery in the foot and leg and is frequently used to evaluate level of motor
56
57
58
59
60

1
2 347 recovery post-stroke in clinical settings. The CMSA foot and leg scores have good intra-rater
3
4 348 (ICCs=0.94-0.98) and inter-rater (ICCs=0.85-0.96) reliability.⁴¹ The MOCA⁴² is a paper-based test that
5
6 349 can be used to screen for mild cognitive impairment; patients are scored on visuospatial and executive
7
8
9 350 function, naming, memory, attention, language, abstraction, delayed recall, and orientation.
10

11 351 We will document the frequency and intensity of exercise during in- and out-patient
12
13 352 rehabilitation by chart review. Participants will complete a questionnaire at baseline that asks about
14
15
16 353 their social supports, employment, familial responsibilities, living situation etc, which are factors that
17
18 354 could influence participation in physical activity. Many of these questions have been adapted from the
19
20 355 Canadian Longitudinal Study on Aging.⁴⁴ Some questions will be repeated at the 6-month post-
21
22 356 discharge time-point to account for lifestyle changes since discharge from rehabilitation. Pre-morbid
23
24
25 357 exercise behaviour will be evaluated with the Schmidt retrospective physical activity scale.⁴⁵ This scale
26
27 358 shows good agreement with previously-completed questionnaires regarding physical activity.⁴⁵ We will
28
29 359 use this scale to estimate participants' average amount of time (hours/day) prior to their strokes spent in
30
31
32 360 sedentary activities (e.g., watching television, sedentary occupational activity) and in physical
33
34 361 recreational activity or exercise.
35

36 362 37 38 39 363 **6.4 Sample size**

40
41 364 We expect that approximately 25% of people who complete GAE⁴⁶ and 50% of individuals who
42
43 365 complete PROPEL²⁴ will be classified as 'active'. A sample of 96 per phase will provide 80% power to
44
45
46 366 detect a 25% to 50% difference at alpha of 0.05 for the 6 sites taking into account an intracluster
47
48 367 correlation of 0.05.⁴⁷ The sample size calculation was run using PASS Version 12 (Hintze, J, 2014,
49
50 368 NCSS, LLC. Kaysville, Utah). We will aim to recruit 120 participants total per phase to account for a
51
52
53 369 conservative 20% drop-out rate.
54
55 370

6.5 Recruitment

There are approximately 710 admissions annually to out-patient stroke rehabilitation at all sites combined. We conservatively estimate that 40% of these individuals will be eligible for the study and, of these, 50% will consent to participate. Thus, we expect to recruit ~140 participants annually to meet the target sample size with ~2 years of recruiting. Target sample sizes for each site are: Hamilton Health Sciences – 24; St Joseph’s Care Group – 24; Sunnybrook Research Institute - St John’s Rehab – 60, Toronto Rehabilitation Institute – Rumsey Centre – 58, Toronto Rehabilitation Institute – University Centre – 58, West Park Healthcare Centre – 60. To encourage recruitment to the study, participants will receive a gift card (\$30 CAD value) as a modest incentive to participate.

In order to generate a CONSORT flow-diagram for participant recruiting,⁴⁸ RA will count the number of individuals who are admitted to the out-patient stroke program and, of these, the number who are referred to the GAE or PROPEL program. The RA will also maintain documentation related to screening and enrolment of potential participants. Identifying or health-related information will not be documented for individuals who do not consent to participate in the study.

7. METHODS: ASSIGNMENT OF INTERVENTIONS

7.1 Intervention allocation

The time at which each site transitions from GAE to PROPEL will be determined by drawing site names at random (Figure 1). One site will implement PROPEL at the start of the study period, whereas one site will never transition to PROPEL; this will help to ensure blinding of assessors (see Section 7.2). The site that does not transition to PROPEL during the study period will be offered training in PROPEL at the end of the study period. Intervention allocation will be performed at the start of the study period by the Principal Investigator, who will not be directly involved in recruiting or data

1
2 394 collection. The Site Leads and PTs at each site will be informed of the transition to PROPEL
3
4 395 approximately 3 months prior to the transition to allow for sufficient time for training and planning.
5

6 396
7

8 397 **7.2 Blinding**

10
11 398 Participants cannot be blinded to intervention allocation, although they will not be aware of the
12
13 399 existence of another intervention arm. Assessors (RA at each site) who collect data, including
14
15 400 administering questionnaires, will be unaware of the time at which the site transitions from GAE to
16
17 401 PROPEL. While it is more likely that a given site will be allocated to GAE at the start of the study
18
19 402 period, and to PROPEL at the end of the study, inclusion of two sites that always complete either GAE
20
21 403 or PROPEL will create uncertainty in intervention allocation at all time points. Furthermore, using
22
23 404 objective methods to collect data pertaining to the primary outcome (i.e., heart rate and activity
24
25 405 monitor) helps to protect against bias if assessors inadvertently become unblinded.
26
27
28

29 406
30

31 407 **8. METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS**

32 408 **8.1 Data collection methods**

33
34 409 Data will be collected primarily by the RA either directly from the participant or by chart review (see
35
36 410 Table 1 for further details). RAs at each site will receive training regarding data collection from the
37
38 411 Principal Investigator (AM) and central Study Coordinator (AA). Questionnaires will be completed via
39
40 412 in person interview at enrolment, and over the telephone at the follow-up time points. Activity monitors
41
42 413 will be sent to participants and returned to the site via mail. Participants will be contacted via telephone
43
44 414 just prior to mailing the activity monitors to remind them that they will be receiving the activity
45
46 415 monitors, and to ensure that they will be home to receive them (e.g., that they are not planning to be on
47
48 416 vacation at that time).
49
50
51
52
53
54
55
56
57
58
59
60

1
2 417 In order avoid losing participants to follow-up, we will request contact information of a friend
3
4 418 or family member. Participants who provide consent for us to contact their friends or family members
5
6 419 will be provided with a contact form at the time when written consent is obtained, and will be asked to
7
8
9 420 return the form at the next visit or by mail (a stamped self-addressed envelope will be provided). This
10
11 421 information will only be used to obtain information about the whereabouts of a research participant if
12
13 422 we are unable to contact them after multiple attempts. Participants will primarily be contacted by
14
15
16 423 telephone throughout the study, unless otherwise requested. Each time they are contacted, participants
17
18 424 will be told when they should next expect to hear from the RA and will be asked to inform the RA of
19
20 425 upcoming limited availability (e.g. due to vacation or scheduled surgery). A letter will be mailed to
21
22 426 participants who are unable to be reached: 1) because his/her telephone number is out of service; or 2)
23
24
25 427 five attempts have been made to telephone the participant over the course of two weeks (with at least
26
27 428 two voicemail messages for participants who have voicemail and have provided consent for us to leave
28
29 429 voicemail). In the latter case, telephone calls will be placed at varying times of the day in an attempt to
30
31
32 430 reach participants who are unavailable at the same time each day due to regular appointments. The
33
34 431 letter will request that participants contact the RA. If the RA does not hear from the participant two
35
36 432 weeks after the letter was mailed, the RA will contact the alternative contact.
37
38
39 433
40

41 434 **8.2 Data management**

42
43 435 Each activity monitor will be linked to an anonymous account and activity monitor data will be stored
44
45 436 on the manufacturer's servers linked to these anonymous accounts. We will document internally which
46
47
48 437 participants' data are associated with which accounts; therefore, there will be no information about
49
50 438 study participants (e.g., name, age, study ID number) stored on the manufacturer's servers. Activity
51
52 439 data will be downloaded from the manufacturer's servers as soon as possible after collection. All other
53
54
55 440 electronic data will be stored at each site on secure institutional servers. Files containing patient names
56
57
58
59
60

1
2 441 and contact information will be password protected and stored separately from other data. Hard copies
3
4 442 of files containing de-identified data will be stored in locked cabinets and/or in offices that are locked
5
6 443 when not occupied. Consent forms will be stored in locked cabinets/offices separately from other data.
7
8
9 444 Only those individuals who require access to the data for the purpose of this study will be provided
10
11 445 with the password to the file containing identifiers and/or the keys to the locked cabinet/office. De-
12
13 446 identified electronic data will be transferred to the main site (Sunnybrook Research Institute) using
14
15
16 447 secure file transfer protocols.
17
18 448
19

20 449 **8.3 Statistical analysis**

21
22
23 450 We will compare cohort descriptors between the two phases (GAE and PROPEL) using t-tests, Mann-
24
25 451 Whitney *U* tests, or chi-square tests, as appropriate. If phases significantly differ at baseline on cohort
26
27 452 descriptors, these measures may be used as covariates in the analysis. To test our primary hypothesis,
28
29
30 453 we will compare the proportion of active and inactive individuals at the final assessment point (6
31
32 454 months post-intervention) using mixed-model logistic regression, with fixed effects of time and phase
33
34 455 and random effect of cluster (site).⁴⁹ We will also examine between-phase differences in physical
35
36 456 activity at the 1-month and 4-month time points, which could reveal short-term benefits of PROPEL,
37
38
39 457 even if there are no differences at 6-months. A similar mixed-model ANOVA will be used to compare
40
41 458 SSEE, SOEE, and BBAQ scores between programs to test the secondary hypotheses. All recruited
42
43 459 participants who comply with data collection will be included in the analysis; participants with missing
44
45
46 460 data for one time point will be excluded from analysis of that variable for that time point.
47
48 461
49

50 462 **9. METHODS: MONITORING**

51 52 463 **9.1 Data monitoring**

53
54
55
56
57
58
59
60

1
2 464 There is no data monitoring committee for this study, as the safety of aerobic exercise has already been
3
4 465 established for this population,^{6 10} and the additional risk of the discussion components of the PROPEL
5
6 466 program and other study components (e.g., questionnaires or activity monitoring) is minimal (see
7
8
9 467 Section 9.2). Adverse events that meet all three of the following criteria will be reported immediately to
10
11 468 the local research ethics board(s), as is routine practice: 1) unexpected in terms of nature, severity, or
12
13 469 frequency; 2) related or possibly related to participation in the research; and 3) suggests an potential
14
15
16 470 increase in risk of harm to research participants or to others. All adverse events will be collated and
17
18 471 evaluated bi-annually by the Principal Investigator (AM).
19

20 472 There is no plan for any interim analysis; interim analysis is not feasible with a SWT design due
21
22
23 473 to the fact that the experimental intervention is ‘rolled out’ gradually to each site, which means that the
24
25 474 number of participants per phase will be uneven until the end of the trial. The trial will be stopped
26
27 475 when one of the following criteria are met: 1) we have recruited at least 120 participants per phase; 2)
28
29
30 476 6-month follow-up data are available for at least 96 participants per phase; or 3) all site investigators
31
32 477 (AM, DB, AT, and DT) agree that continuing the trial will not be feasible (e.g., due to lower than
33
34 478 expected recruiting and lack of funding to continue the trial).
35

36 479 37 38 39 480 **9.2 Potential harms and auditing**

40
41 481 Sites will implement two interventions as part of routine care (GAE or PROPEL). Some aerobic
42
43 482 exercise is currently conducted at all sites, but might not be implemented in the systematic manner
44
45
46 483 required for this study. However, aerobic exercise is recommended as part of stroke rehabilitation
47
48 484 within the Canadian Stroke Best Practice Recommendations.⁵⁰ Furthermore, with appropriate screening
49
50 485 and prescription, aerobic exercise is safe and feasible early after stroke.¹⁰ Treating physiotherapists will
51
52
53 486 screen patients, with appropriate consultation with the inter-professional team, and provide the exercise
54
55 487 prescription following established guidelines for aerobic exercise after stroke,⁵¹ prior to referring them
56
57
58
59
60

1
2 488 to GAE or PROPEL. The interventions will be supervised by a trained registered physiotherapist, who
3
4 489 will continue to monitor patients' response to exercise and may choose to adjust the intensity or
5
6 490 duration of exercise to minimize risk to participants.
7

8
9 491 Heart rate and blood pressure will be measured at rest at the start of each intervention session to
10
11 492 obtain a baseline measure of cardiovascular function. If measured blood pressure or heart rate is outside
12
13 493 of an acceptable range (systolic blood pressure: 90-140 mmHg; diastolic blood pressure: 60-90 mmHg;
14
15 494 heart rate: 60-100 bpm) a second measure will be obtained. If the 2nd measurement reveals elevated
16
17 495 heart rate and/or blood pressure, the participant will be allowed to rest seated for 5 minutes, after which
18
19 496 measurements will be retaken. If the 2nd measurement reveals low heart rate and/or blood pressure, the
20
21 497 participant will be offered a glass of water and measurements will be retaken after 5 minutes.
22
23

24
25 498 Participants with heart rate/blood pressure measurements outside the acceptable range will also be
26
27 499 questioned regarding recent medications (what they have taken and when, or if they have not taken
28
29 500 their usual medications), when they last had something to eat and drink, and if they recently took
30
31 501 caffeine or exercised. The decision to continue or terminate the session will be made by the PT
32
33 502 considering factors such as the participants' usual resting heart rate/blood pressure, how far the
34
35 503 measured values are outside of the acceptable range, the participants' usual medications (e.g., beta-
36
37 504 blockers), and the participants' perception of how they are feeling. If the session is terminated, the PT
38
39 505 may consult with the patients' physiatrist or other physician.
40
41
42

43 506 The Canadian Stroke Best Practice Recommendations also recommend including a plan to
44
45 507 enable patients to continue to exercise post-discharge, including addressing barriers to physical
46
47 508 activity.⁵⁰ However, the specific education, self-management, and problem-solving components of the
48
49 509 PROPEL program are not part of routine care at all sites. The additional risk to participants in
50
51 510 completing this component of the PROPEL program is minimal. Participants can opt out of any part of
52
53 511 the discussion if they feel uncomfortable.
54
55
56
57
58
59
60

1
2 512 The additional measures conducted as part of the study pose minimal risk to participants. The
3
4 513 CMSA, NIH-SS, and MOCA are frequently conducted as part of clinical care in stroke rehabilitation.
5
6 514 Other measures are questionnaires which ask routine questions about physical activity behaviour and
7
8
9 515 lifestyle. Despite the minimal risk involved in these measures, participants will be reminded that they
10
11 516 can opt out of any testing and/or decline to answer any of the questions in the questionnaires. The
12
13 517 activity monitoring also poses minimal risk to participants; the devices are available commercially and
14
15 518 are worn daily by millions of individuals around the world. Participants may develop skin irritation
16
17
18 519 from wearing the device daily; they will be instructed to remove the device if this occurs. Participants
19
20 520 may feel burdened by donning and doffing the activity monitors each day.

21
22
23 521 The study PT will document any adverse events that occur during the interventions; the RA will
24
25 522 document adverse events for participants who enrol in the study during the follow-up period.
26

27 523 28 29 524 **10. ETHICS AND DISSEMINATION**

30 31 525 **10.1 Research ethics approval**

32
33
34 526 Research ethics approval has been received by the Research Ethics Board of the University Health
35
36 527 Network (Study ID: 16-5916, approved 14 November 2016), which covers two sites (Toronto
37
38
39 528 Rehabilitation Institute – University Centre, and Toronto Rehabilitation Institute – Rumsey Centre). As
40
41 529 of this writing, research ethics approval is pending at the other four sites.
42

43 530 44 45 531 **10.2 Protocol amendments**

46
47
48 532 Substantive changes to the design or conduct of the study will require a formal amendment to the study
49
50 533 protocol. Such substantive amendments will be agreed upon by the site investigators (AM, DB, AT and
51
52 534 DT) and will be approved by the local Research Ethics Boards prior to implementation locally. Minor
53
54
55
56
57
58
59
60

1
2 535 administrative changes to study documents (e.g., correcting a typographical error or clarifying a
3
4 536 questionnaire item) may also be implemented, with the Research Ethics Boards notified of the changes.
5

6 537

9 538 **10.3 Consent**

10
11 539 Potential participants will be assessed for eligibility by the study PT within the final two weeks of the
12
13 540 patients' participation in the GAE/PROPEL programs. The study PT, who is in the patients' circle of
14
15
16 541 care, will ask eligible patients if they are interested in speaking with the RA about participating in the
17
18 542 study. The RA will discuss the study at a time that is convenient for interested individuals. S/he will
19
20 543 describe the study, as outlined in the consent form (Appendix) and will answer any questions the
21
22 544 patient may have about the study. The patient will be provided with a copy of the consent form and will
23
24
25 545 be invited to discuss the study with friends or family members, and/or to take some time to think about
26
27 546 being involved in the study. If a patient indicates that s/he would like to participate in the study, s/he
28
29 547 will be asked to sign the consent form. At that time, the RA will arrange a time that is convenient for
30
31
32 548 the participant to collect baseline data (see Section 6.4.3). We will assume that patients who do not
33
34 549 provide consent to the study within two weeks after they finish the GAE/PROPEL program are not
35
36 550 interested in participating in the study.
37

38 551

41 552 **10.4 Confidentiality**

42
43 553 The study PT will run the GAE and PROPEL interventions as part of routine care at each site. Patients
44
45 554 who are referred to GAE or PROPEL may decline participation in the study. Therefore, individuals
46
47
48 555 who do not consent to the study may participate in GAE or PROPEL. The study PT will be an
49
50 556 individual who also has a role in clinical care on the stroke program at the site and, therefore, will
51
52 557 already be part of the circle of care. The study PT will not have a role in recruiting participants into the
53
54
55 558 study, other than to introduce the study and, if interested, introduce the RA to potential participants.
56

57

58

59

60

1
2 559 Identifiable information (participant names and contact information) will be stored separately
3
4 560 from health information and study data (see also Section 8.2) in a password protected file, with the
5
6 561 password only known to those individuals who are responsible for data collection. A participant ID
7
8
9 562 number will be used to link identifiable information with health information and study data. The link
10
11 563 between the participant ID number and name will be destroyed after data have been collected and
12
13 564 verified. De-identified data will be kept in a secure and confidential location for 10 years.
14
15

16 565

18 566 **10.5 Declaration of interests**

19

20 567 The authors declare that they have no competing interests related to this study.
21
22

23 568

25 569 **10.6 Access to data**

26

27 570 The Principal Investigator (AM) and biostatistician (AK) will have access to the full dataset. The site
28
29 571 investigators will have access to data collected locally. A study co-investigator or collaborator may be
30
31
32 572 granted access to the full dataset for secondary analysis with approval of all site investigators (AM,
33
34 573 DB, AT, and DT) and the coordinating institution (Sunnybrook Research Institute).
35

36 574

39 575 **10.7 Ancillary and post-trial care**

40

41 576 Each site will be responsible for providing out-of-pocket expenses to ensure that a participant receives
42
43 577 immediate medical care in the event that the participant experiences an adverse health event (e.g.
44
45 578 injury) as a result of participation in the study.
46
47

48 579

50 580 **10.8 Dissemination policy**

51

52 581 Study participants will receive a letter of appreciation at the end of the study, which may include a very
53
54
55 582 brief summary of the study results. Study results will be disseminated to others via publication in a
56
57
58

1
2 583 peer-reviewed journal. We will aim to submit a paper describing analysis of the primary and secondary
3
4 584 outcomes within 6 months of completing data collection. All individuals who meet the International
5
6 585 Committee of Medical Journal Editors criteria for authorship will be included as authors on any
7
8
9 586 publications arising from this work. There is no current plan to make the participant-level dataset
10
11 587 available publicly; however, the dataset may be made available in future via a Data Access Committee,
12
13 588 if such a committee is established by the coordinating institution.
14

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

11. REFERENCES

1. Tang A, Sibley KM, Thomas SG, McIlroy WE, Brooks D. Maximal exercise test results in subacute stroke. *Arch Phys Med Rehabil* 2006;87:1100-1105.
2. Brooks D, Tang A, Sibley K, McIlroy WE. Profile of patients at admission into an inpatient stroke rehabilitation program: cardiorespiratory fitness and functional characteristics. *Physiother Can* 2008;60(2):171-179.
3. MacKay-Lyons MJ, Makrides L. Exercise capacity early after stroke. *Arch Phys Med Rehabil* 2002;83:1697-1702.
4. Rimmer JH, Wang E. Aerobic exercise training in stroke survivors. *Top Stroke Rehabil* 2005;12(1):17-30.
5. Tang A, Marzolini S, Oh P, McIlroy WE, Brooks D. Feasibility and effects of adapted cardiac rehabilitation after stroke: a prospective trial. *BMC Neurol* 2010;10:40.
6. Tang A, Sibley KM, Thomas SG, Bayley M, Richardson D, McIlroy WE, et al. Effects of an aerobic exercise program on aerobic capacity, spatiotemporal gait parameters, and functional capacity in subacute stroke. *Neurorehabil Neural Repair* 2009;23:389-397.
7. Stoller O, de Bruin ED, Knols RH, Hunt JJ. Effects of cardiovascular exercise early after stroke: systematic review and meta-analysis. *BMC Neurology* 2012;12:45.
8. Saunders DH, Sanderson M, Brazzelli M, Gerig CA, Mead GE. Physical fitness training for stroke patients. *Cochrane Database Syst Rev* 2013(10):CD003316.
9. Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Mortag Johnson C, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;45:2532-2553.
10. Biasin L, Sage MD, Brunton K, Fraser JE, Mileris R, Howe J, et al. Integrating aerobic training within sub-acute stroke rehabilitation: a feasibility study. *Phys Ther* 2014;94(12):1796-1806.

- 1
2 613 11. Michael KM, Allen JK, Macko RF. Reduced ambulatory activity after stroke: the role of balance,
3
4 614 gait, and cardiovascular fitness. *Arch Phys Med Rehabil* 2005;86:1552-1556.
5
6 615 12. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many
7
8
9 616 steps/day are enough? For older adults and special populations. *Int J Behav Nutr Phys Act*
10
11 617 2011;8:80.
12
13 618 13. Baert I, Feys H, Daly D, Troosters T, Vanlandewijck Y. Are patients 1 year post-stroke active
14
15
16 619 enough to improve their physical health? *Disabil Rehabil* 2012;34(7):574-580.
17
18 620 14. Morris JH, Williams B. Optimising long-term participation in physical activities after stroke:
19
20 621 exploring new ways of working for physiotherapists. *Physiotherapy* 2009;95:227-233.
21
22 622 15. Rosenberg DE, Bombardier CH, Hoffman JM, Belza B. Physical activity among persons aging with
23
24
25 623 mobility disabilities: shaping a research agenda. *J Aging Res* 2011;2011:708510.
26
27 624 16. Jones TM, Dean CM, Hush JM, Dear BF, Titov N. A systematic review of the efficacy of self-
28
29
30 625 management programs for increasing physical activity in community-dwelling adults with
31
32 626 acquired brain injury. *Systematic Reviews* 2015;4:51.
33
34 627 17. Morris JH, MacGillivray S, Mcfarlane S. Interventions to promote long-term participation in
35
36 628 physical activity after stroke: a systematic review of the literature. *Arch Phys Med Rehabil*
37
38
39 629 2014;95:956-967.
40
41 630 18. Kim H, Kim O. The lifestyle modification coaching program for secondary stroke prevention. *J*
42
43 631 *Korean Acad Nurs* 2013;43(3):331-340.
44
45 632 19. Damush TM, Ofner S, Yu Z, Plue L, Nicholas G, Williams LS. Implementation of a stroke self-
46
47
48 633 management program: a randomized controlled pilot study of veterans with stroke. *Transl*
49
50 634 *Behav Med* 2011;1(4):561-572.
51
52
53
54
55
56
57
58
59
60

- 1
2 635 20. Gillham S, Endacott R. Impact of enhanced secondary prevention on health behaviour in patients
3
4 636 following minor stroke and transient ischaemic attack: a randomized controlled trial. *Clin*
5
6 637 *Rehabil* 2010;24:822-830.
- 8
9 638 21. Huijbregts M, Myers A, Streiner D, Teasell R. Implementation, process and preliminary outcomes
10
11 639 evaluation of two community programs for persons with stroke and their care partners. *Top*
12
13 640 *Stroke Rehabil* 2008;15:503-520.
- 15
16 641 22. van der Ploeg HP, Streppel KRM, van der Beek AJ, van der Woude LHV, Vollenbroek-Hutten
17
18 642 MMR, van Harten WH, et al. Successfully improving physical activity behavior after
19
20 643 rehabilitation. *American Journal of Health Promotion* 2007;21(3):153-159.
- 22
23 644 23. Zalewski KR, Dvorak L. Barriers to physical activity between adults with stroke and their care
24
25 645 partners. *Top Stroke Rehabil* 2011;18(Suppl 1):666-675.
- 26
27 646 24. Mansfield A, Knorr S, Poon V, Inness EL, Middleton L, Biasin L, et al. Promoting Optimal
28
29 647 Physical Exercise for Life (PROPEL) - an exercise and self-management program to encourage
30
31 participation in physical activity after discharge from stroke rehabilitation: a feasibility study.
32 648
33
34 649 *Stroke Res Treat* 2016;2016:9476541.
- 35
36 650 25. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. Quantity and
37
38 quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and
39 651
40 neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci*
41 652
42
43 653 *Sports Exerc* 2011;43(7):1334-1359.
- 44
45 654 26. Copas AJ, Lewis JJ, Thompson JA, Davey C, Baio G, Hargreaves JR. Designing a stepped wedge
46
47 trial: three main designs, carry-over effects and randomisation approaches. *Trials* 2015;16:352.
- 48 655
49
50 656 27. Mdege ND, Man M-S, Taylor CA, Torgerson DJ. Systematic review of stepped wedge cluster
51
52 randomized trials shows that design is particularly used to evaluate interventions during routine
53 657
54
55 658 implementation. *J Clin Epidemiol* 2011;64:936-948.
- 56
57
58
59
60

- 1
2 659 28. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised
3
4 660 trial: rationale, design, analysis, and reporting. *Br Med J* 2015;351:h391.
5
6 661 29. Prochaska JO, Di Clemente CC. Transtheoretical therapy: toward a more integrative model of
7
8 change. *Psychother: Theor Res* 1982;19(3):276-288.
9 662
10
11 663 30. Bandura A. Health promotion by social cognitive means. *Health Educ Behav* 2004;31(2):143-164.
12
13 664 31. Bandura A. *Self efficacy. The exercise of control*. New York: W.H. Freeman, 1997.
14
15
16 665 32. Kinne S, Patrick DL, Maher EJ. Correlates of exercise maintenance among people with mobility
17
18 666 impairments. *Disabil Rehabil* 1999;21(1):15-22.
19
20 667 33. Reed M, Harrington A, Duggan A, Wood VA. Meeting stroke survivors perceived needs: a
21
22 qualitative study of community-based exercise and education scheme. *Clin Rehabil*
23 668
24 2010;24(1):16-25.
25 669
26
27 670 34. Resnick B, Michael K, Shaughnessy M, Nahm ES, Kobunek S, Sorkin J, et al. Inflated perceptions
28
29 of physical activity after stroke: pairing self-report with physiologic measures. *J Phys Act*
30 671
31 *Health* 2008;5(2):308-318.
32 672
33
34 673 35. Klassen TD, Simpson LA, Lim SB, Louie DR, Parappilly B, Sakakibara BM, et al. "Stepping up"
35
36 674 activity poststroke: ankle-positioned accelerometer can accurately record steps during slow
37
38 walking. *Phys Ther* 2016;96(3):355-360.
39 675
40
41 676 36. Washburn RA, Zhu W, McAuley E, Frogley M, Figoni SF. The Physical Activity Scale for
42
43 677 Individuals with Physical Disabilities: development and evaluation. *Arch Phys Med Rehabil*
44
45 678 2002;83:193-200.
46
47
48 679 37. van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Vollenbroek-Hutten M, van
49
50 680 Mechelen W. The Physical Activity Scale for Individuals with Physical Disabilities: test-retest
51
52 681 reliability and comparison with an accelerometer. *J Phys Act Health* 2007;4(1):96-100.
53
54
55
56
57
58
59
60

1

2 682

3

4 683

5

6 684

7

8

9 685

10

11 686

12

13 687

14

15

16 688

17

18 689

19

20 690

21

22

23 691

24

25 692

26

27 693

28

29 694

30

31

32 695

33

34 696

35

36 697

37

38

39 698

40

41 699

42

43 700

44

45 701

46

47

48 702

49

50 703

51

52

53

54

55

56

57

58

59

60

38. Shaughnessy M, Resnick BM, Macko RF. Reliability and validity testing of the Short Self-Efficacy and Outcome Expectation for Exercise Scales in stroke survivors. *J Stroke Cerebrovasc Dis* 2004;13(5):214-219.
39. Barriers to Being Active Quiz: Centers for Disease Control and Prevention.
40. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. *Arch Neurol* 1989;46(6):660-662.
41. Gowland C, Stratford P, Ward M, Moreland J, Torresin W, Van Hullenaar S, et al. Measuring physical impairment and disability with the Chedoke-McMaster Stroke Assessment. *Stroke* 1993;24:58-63.
42. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Colin I, et al. The Montreal cognitive assessment (MoCA): a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695-699.
43. Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;5:603-612.
44. Raina P, Wolfson C, Kirkland S. Canadian Longitudinal Study on Aging (CLSA) Protocol, 2013.
45. Schmidt ME, Slinger T, Chang-Claude J, Wahrendorf J, Steindorf K. Evaluation of a short retrospective questionnaire for physical activity in women. *Eur J Epidemiol* 2006;21:575-585.
46. Brown C, Fraser JE, Inness EL, Wong J, Middleton LE, Poon V, et al. Does participation in standardized aerobic fitness training during inpatient stroke rehabilitation promote engagement in aerobic exercise after discharge? A cohort study. *Top Stroke Rehabil* 2014;21(Suppl 1):S42-51.
47. Donner A, Klar N. *Design and analysis of cluster randomized trials in health research*. London: Arnold, 2000.

- 1
2 704 48. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for
3
4 705 improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;357:1191-
5
6 706 1194.
7
8
9 707 49. Davey C, Hargreaves J, Thompson JA, Copas AJ, Beard E, Lewis JJ, et al. Analysis and reporting
10
11 708 of stepped wedge randomised controlled trials: synthesis and critical appraisal of published
12
13 709 studies, 2010 to 2014. *Trials* 2015;16:358.
14
15
16 710 50. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, et al. Canadian stroke best
17
18 711 practice recommendations: stroke rehabilitation practice guidelines, update 2015. *Int J Stroke*
19
20 712 2016;11(4):459-484.
21
22
23 713 51. MacKay-Lyons M, Macko R, Eng J, Billinger S, Hafer-Macko C, Suskin N, et al. Aerobic exercise
24
25 714 recommendations to optimize best practices in care after stroke, 2012.
26
27 715
28
29 716
30
31 717
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12. TABLES

Table 1: Overview of data collection time points.

	Study enrolment	1-month post-discharge	4-months post-discharge	6-months post-discharge
<i>Cohort descriptors</i>				
Chart review form	RA-CR			
NIH-SS	RA-P			
CMSA	RA/PT-CR/P			
MOCA	RA-P			
Baseline questionnaire	RA-P			
6-month follow-up questionnaire				RA-P
Schmidt questionnaire	RA-P			
<i>Primary outcomes</i>				
FitBit activity monitoring*		RA-P	RA-P	RA-P
FitBit heart rate data*		RA-P	RA-P	RA-P
PASIPD**		RA-P	RA-P	RA-P
<i>Secondary outcomes</i>				
SSEE	RA-P			
SOEE	RA-P			
BBAQ		RA-P		

Outcomes: BBAQ=Barriers to Being Active Quiz; CMSA=Chedoke-McMaster Stroke Assessment; MOCA=Montreal Cognitive Assessment; NIH-SS=National Institutes of Health Stroke Scale; PASIPD=Physical Activity Scale for Individuals with Physical Disabilities; SOEE=Short Outcome Expectations for Exercise scale; SSEE=Short Self-Efficacy for Exercise scale.

Data collection: PT-CR=data collected by the physiotherapist by chart review; PT-P=data collected by the physiotherapist directly from the participant; RA-CR=data collected by the research assistant from chart review; RA-P=data collected by research assistant directly from the participant.

*Activity and heart rate monitoring for 7 days continuously

**PASIPD questionnaire should be done at the end of the 7-day activity/heart rate monitoring period.

13. FIGURE CAPTIONS

Figure 1: Intervention allocation schedule. G1, G2 etc. are the 6-week long group aerobic exercise

(GAE) or PROPEL groups. Each site should be able to complete 8 groups per year; however, only 7

groups will be completed in 2017 to allow for additional time at the start of the year to obtain research

ethics approval, inter-institutional agreements, and pilot implementation at all sites (see also Figure 3).

'0' indicates that the site will complete GAE in that time period, whereas '1' indicates that they will

complete PROPEL. A simple randomization procedure will be used to determine the time at which

each site transitions from GAE to PROPEL. Sites will be allocated in order by drawing names from a

hat; e.g., the 1st site to be drawn will be Site A, the 2nd will be Site B, etc.

Figure 2: Hypothetical timeline for one participant. The exact timing of in- and out-patient

rehabilitation will vary for each participant. The sub-maximal aerobic capacity test is completed during

in-patient rehabilitation. After this point the participant could participate in individual or open-group

aerobic exercise during in- and out-patient rehabilitation (while waiting to be enrolled in the study

intervention). The closed-group study intervention (group aerobic exercise (GAE) only or PROPEL)

will likely start during out-patient rehabilitation, though some patients may start during in-patient

rehabilitation. The participant will be enrolled in the study at the end of the study intervention, at which

point cohort descriptors, the Short Self-Efficacy for Exercise (SSEE) scale, and the Short Outcome

Expectations for Exercise (SOEE) scale will be collected. Activity monitoring will be conducted for 7

days continuously at three time points: 1) one month; 2) 4 months; 3) and 6 months after the end of the

study intervention. The Barriers to Being Active Quiz (BBAQ) will be conducted at the 1-month post-

intervention time point.

	2017							2018							
	G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12	G13	G14	G15
Site A	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Site B	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1
Site C	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1
Site D	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
Site E	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
Site F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Figure 1: Intervention allocation schedule. G1, G2 etc. are the 6-week long group aerobic exercise (GAE) or PROPEL groups. Each site should be able to complete 8 groups per year; however, only 7 groups will be completed in 2017 to allow for additional time at the start of the year to obtain research ethics approval, inter-institutional agreements, and pilot implementation at all sites (see also Figure 3). '0' indicates that the site will complete GAE in that time period, whereas '1' indicates that they will complete PROPEL. A simple randomization procedure will be used to determine the time at which each site transitions from GAE to PROPEL. Sites will be allocated in order by drawing names from a hat; e.g., the 1st site to be drawn will be Site A, the 2nd will be Site B, etc.




Figure 2: Hypothetical timeline for one participant. The exact timing of in- and out-patient rehabilitation will vary for each participant. The sub-maximal aerobic capacity test is completed during in-patient rehabilitation. After this point the participant could participate in individual or open-group aerobic exercise during in- and out-patient rehabilitation (while waiting to be enrolled in the study intervention). The closed-group study intervention (group aerobic exercise (GAE) only or PROPEL) will likely start during out-patient rehabilitation, though some patients may start during in-patient rehabilitation. The participant will be enrolled in the study at the end of the study intervention, at which point cohort descriptors, the Short Self-Efficacy for Exercise (SSEE) scale, and the Short Outcome Expectations for Exercise (SOEE) scale will be collected. Activity monitoring will be conducted for 7 days continuously at three time points: 1) one month; 2) 4 months; 3) and 6 months after the end of the study intervention. The Barriers to Being Active Quiz (BBAQ) will be conducted at the 1-month post-intervention time point.

CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY

Title of the study: Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: a randomized trial

Principal investigator

Avril Mansfield, PhD
Scientist, Toronto Rehabilitation Institute – UHN
Phone: 416-597-3422 ext. 7831

Contact Information

Anthony Aqai, MSc
Clinical Research Analyst, Toronto Rehabilitation Institute – UHN
Phone: 416-597-3422 ext 7826

Funding

This study is funded by the Canadian Institutes of Health Research

Introduction

You are being asked to take part in a research study. Please read the information about the study presented in this form. The form includes details on study's risks and benefits that you should know before you decide if you would like to take part. You should take as much time as you need to make your decision. You should ask the study staff to explain anything that you do not understand and make sure that all of your questions have been answered before signing this consent form. Before you make your decision, feel free to talk about this study with anyone you wish including your friends, family, and family doctor. Participation in this study is voluntary.

Background and purpose

Research shows that physical exercise is good for people with stroke. However, many people with stroke do not perform enough exercise. The purpose of this study is to see if a fitness program delivered during rehabilitation helps people with stroke to be more physically active *after* leaving the rehabilitation hospital. You are being asked to participate in this study because you completed this fitness program during your rehabilitation stay at the Toronto Rehabilitation Institute.

Study visits and procedures

If you agree to participate in this study, we will measure how much physical activity you do over the 6-months after you finish out-patient rehabilitation at the Toronto Rehabilitation Institute. We will do this by asking you to wear an activity monitor on your wrist for three 1-week periods: 1-month, 4-months, and 6-months after you finish rehabilitation. The activity monitor looks like a watch and counts how many steps you take during the day. It also measures how fast your heart is beating. We will mail the activity monitor to you and ask you to return it in a postage-paid envelope. You can remove the activity monitor before you go to bed. You should remove the activity monitor before bathing/showing, if you go swimming, if it becomes uncomfortable to wear, or if you are requested to do so for any medical care.

Wrist activity monitor



Time	Time commitment	Tests and procedures	Location
Around the time of discharge from the hospital	~30 minutes	Tests of leg function, and memory Questionnaires about previous exercise habits and how you feel about exercise	Toronto Rehab
1-month post-discharge	~30 minutes	Activity monitoring Questionnaire about your physical activities	Your home (telephone call)
4-months post-discharge	~30 minutes		
6-months post-discharge	~30 minutes		

Some types of exercise might not be recorded by the activity monitor; for example, if you go swimming or do exercises where you don't walk around a lot (like seated exercises at home). For this reason, we will also ask you to complete a questionnaire about your physical activities. A research assistant will call you to ask you to complete this questionnaire three times: 1-month, 4-months, and 6-months after you finish rehabilitation. The questionnaire will take about 10-15 minutes to complete. At these time points, the research assistant will also ask you if there have been any changes to your health since he last spoke to you.

With your permission we will obtain information from your clinical chart such as your age, gender, height, weight, information about your stroke and the effects it has had

1
2 on you, and information about your medical conditions and medications. You do not
3 have to do anything extra for this chart review. Before you are discharged from the
4 rehabilitation hospital, we will also measure your leg function, and you memory and
5 will ask you some questions about yourself, your previous exercise habits, and how
6 you feel about exercise. It will take about 30 minutes to perform these measures; we
7 will schedule the testing at a time that is convenient for you. This information is
8 necessary in order to describe the group of people who are participating in this
9 study.
10
11
12

13 **Potential harms, discomforts and inconveniences**

14 There is some extra time involved with participating in this study. You might find this
15 a burden. We think it will take about 3 hours to complete all of the parts of this study.
16 This time commitment will be spread out over 6 months. You might find that it is a
17 burden to wear the activity monitor every day for three 1-week periods or to mail the
18 activity monitors back to us.
19
20
21
22

23 There is a small chance that you will feel uncomfortable answering some of the
24 questions related to the study. You are free to choose not to answer any question.
25
26

27 There is a small chance you will develop a skin irritation from wearing the activity
28 monitor. Removing the activity monitor at night might help to prevent this from
29 happening. If you do develop a skin irritation on your wrist, remove the activity
30 monitor and call the research assistant to let him know.
31
32
33

34 **Potential benefits**

35 You will not directly benefit from being in this study. Information learned from this
36 study may give us more information about how to increase participation in exercise
37 in people with stroke after they leave rehabilitation. These results could be used to
38 benefit other people with stroke in the future.
39
40
41

42 **Reminders and responsibilities**

43 It is important to remember the following things during the study:

- 44 • Tell the study staff your health history and medications as accurately as
45 possible. This will help to prevent any harm to you.
- 46 • Ask the study staff about anything that worries you.
- 47 • Tell the study staff if anything about your health has changed.
- 48 • Wear the activity monitors every day for a week on three different
49 occasions, and return them to us in the postage-paid envelope.
50
51
52
53
54
55
56
57
58
59
60

Confidentiality

Personal Health Information

If you agree to join this study, the research team will collect your personal health information. Personal health information is any information that could identify you and includes your:

- name,
- age,
- telephone number, and
- existing medical records, including types, dates and results of medical tests or procedures.

Representatives of the University Health Network Research Ethics Board may look at the study records and at your personal health information to check that the information collected for the study is correct and to make sure the study is following proper laws and guidelines.

The research team will keep any personal health information about you in a secure and confidential location for 10 years. A list linking your study number with your name will be kept by the research team in a secure place, separate from your study file.

Study information that does not identify you

This is a multi-site study; Sunnybrook Research Institute is the lead site for this study. Some study information will be sent outside of the hospital to Sunnybrook Research Institute. Any information that is sent out of the hospital will have a code and will not show your name or address, or any information that directly identifies you.

All information collected during this study, including your personal health information, will be kept confidential. Information from the activity monitors will be stored on the manufacturer's web servers; however, this information will be completely anonymous and will not be associated with any information that could identify you. Your personal health information will not be shared with anyone outside of the study unless required by law. You will not be named in any reports, publications, or presentations that may come from this study.

Voluntary participation

You are encouraged to ask any questions that you may have about this study. If you do not wish to participate in this study, it will not affect any treatment that you receive at Toronto Rehabilitation Institute – UHN, either now or in the future.

1
2 Your participation in this study is voluntary. You may decide not to be in this study,
3 or to be in the study now and then change your mind later. We will give you any new
4 information that is learned during the study that might affect your decision to stay in
5 the study.
6
7

8 **Withdrawal from study**

9
10 If you chose to participate initially but wish to withdraw at a later date, for any
11 reason, it will not affect the current or future care that you receive at Toronto
12 Rehabilitation Institute – UHN. If you decide to withdraw from the study, the
13 information that was collected before you leave the study will still be used in order to
14 help answer the research question. No new information will be collected without
15 your permission.
16
17

18 **Costs and reimbursement**

19
20 Participation in this study will not involve any additional costs to you. You will
21 receive a \$30 gift card after completing all parts of the study as a token of our
22 appreciation for your participation.
23
24

25 **Rights as a participant**

26
27 If you are harmed as a direct result of taking part in this study, all necessary
28 medical treatment will be made available to you at no cost.
29
30

31
32 By signing this form you do not give up any of your legal rights against the
33 investigators, sponsor or involved institutions for compensation, nor does this
34 form relieve the investigators, sponsor or involved institutions of their legal and
35 professional responsibilities.
36
37

38 **Conflict of interest**

39
40 Researchers have an interest in completing this study. Their interests should not
41 influence your decision to participate in this study.
42
43

44 **Questions about the study**

45
46 If you have any questions, concerns or would like to speak to the study team for
47 any reason, please call the Principal Investigator Avril Mansfield at 416-597-3422
48 extension 7831. **If you have any questions about your rights as a research
49 participant or have concerns about this study, call the Chair of the
50 University Health Network Research Ethics Board (UHN REB) or the
51 Research Ethics office number at 416-581-7849.** The REB is a group of people
52 who oversee the ethical conduct of research studies. The UHN REB is not part of
53 the study team. Everything that you discuss will be kept confidential.
54 You will be given a copy of this form.
55
56
57
58
59

Consent

This study has been explained to me and any questions I had have been answered. I know that I may leave the study at any time. I agree to the use of my information as described in this form. I agree to take part in this study.

In some cases when we are unable to contact you directly, may we leave a voice message (if applicable)? No personal health information will be included in the voice message.

Yes _____(initials) No _____(initials)

If we have been unable to contact you after repeated attempts by telephone or mail, may we contact a friend or family member? We will ask for your friend or family member's contact information in a separate document. We will not share any of your personal health information with your friend or family member.

Yes _____(initials) No _____(initials)

Study participant's name Signature Date

My signature means that I have explained the study to the participant named above. I have answered all questions.

Name of person obtaining consent Signature Date

Was the participant assisted during the consent process? YES NO

If **YES**, please check the relevant box and complete the signature space below:

The consent form was read to the participant. The person signing below attests that the study as set out in this form was accurately explained to, and has had any questions answered.

Name of witness Signature Date

Relationship to participant



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3-5
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1-2
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	1-2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47**Introduction**

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	8-9
	6b	Explanation for choice of comparators	8
Objectives	7	Specific objectives or hypotheses	9
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	9-10

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	10
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	11-12
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12-14
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	12-14
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14-17
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 2

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	18
6				
7				
8	Methods: Assignment of interventions (for controlled trials)			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	18-19
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	18-19
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	18-19
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	19
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	19-20
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	20
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	20-21
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	21
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	21
13				
14				
15	Methods: Monitoring			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	22
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	22-24
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	22-24
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	24
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	24-25
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	25
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	25-26
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	26
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	26
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	26
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	26-27
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	27
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	27
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40

BMJ Open

Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-015843.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Mar-2017
Complete List of Authors:	Mansfield, Avril; Toronto Rehabilitation Institute, Brooks, Dina; University of Toronto, Physical Therapy Tang, Ada; McMaster University, School of Rehabilitation Science Taylor, Denise; St Joseph's Care Group Inness, Elizabeth; Toronto Rehabilitation Institute, Balance Mobility and Falls Clinic Kiss, Alex; Sunnybrooke Research Institute, Department of Research Design and Biostatistics Middleton, Laura; University of Waterloo, Kinesiology; Sunnybrook Research Institute, Heart and Stroke Foundation Centre for Stroke Recovery Biasin, Louis; Toronto Rehabilitation Institute, Balance Mobility and Falls Clinic Fleck, Rebecca; Hamilton Health Sciences, Regional Rehabilitation Program French, Esmé; Northwestern Ontario Regional Stroke Network LeBlanc, Kathryn; Hamilton Health Sciences, Regional Rehabilitation Program Aqui, Anthony; Toronto Rehabilitation Institute Danells, Cynthia; Toronto Rehabilitation Institute
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Neurology
Keywords:	Stroke < NEUROLOGY, Exercise, Behaviour change, Physical activity, Physiotherapy

SCHOLARONE™
Manuscripts

1. ADMINISTRATIVE INFORMATION

Title: Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial

Authors: Avril Mansfield,^{1,3} Dina Brooks,^{1,3,4} Ada Tang,⁵ Denise Taylor,^{6,7} Elizabeth L Inness,^{1,3} Alex Kiss,² Laura Middleton,^{1,8} Louis Biasin,^{1,3} Rebecca Fleck,⁹ Esmé French,¹⁰ Kathryn LeBlanc,⁹ Anthony Aqui,¹ Cynthia Danells^{1,3}

Corresponding author: Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca

Affiliations: ¹Toronto Rehabilitation Institute, Toronto, ON, Canada; ²Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada; ³Department of Physical Therapy, University of Toronto, Toronto, ON, Canada; ⁴West Park Healthcare Centre, Toronto, ON, Canada; ⁵School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada; ⁶St Joseph's Care Group, Thunder Bay, ON, Canada; ⁷Northern Ontario School of Medicine, West Campus, Thunder Bay, ON, Canada; ⁸Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada; ⁹Regional Rehabilitation Program, Hamilton Health Sciences, Hamilton, ON, Canada; ¹⁰Northwestern Ontario Regional Stroke Network, Thunder Bay, ON, Canada

Key words: Stroke; Exercise; Physical Activity; Behaviour Change; Physiotherapy

Word count: 6,704

Protocol version date: 6 March 2017; Original

Funding: This study is supported by the Canadian Institutes of Health Research (PJT-148906). AM holds a New Investigator Award from the Canadian Institutes of Health Research (MSH-141983). DB holds a Canada Research Chair. AT is supported by a personnel award from the Heart and Stroke Foundation, Ontario Provincial Office (CS I 7468). These funding sources had no role in the design of

1
2 25 this study and will not have any role during its execution, analyses, interpretation of the data, or
3
4 26 decision to submit results.
5

6 27 **Roles:** AM conceived of the study, is the grant holder, and drafted the manuscript. AM, DB, AT, and
7
8 28 DT will lead implementation of the study at each site, with assistance from ELI, LB, RF, EF, KL, and
9
10 29 CD. ELI, LB, and CD developed the intervention. AK provided statistical expertise and will conduct
11
12 30 the primary statistical analysis. AM, DB, AT, DT, ELI, AK, LM, LB, RF, EF, KL, AA, and CD
13
14 31 contributed to refining the study protocol and approved the final manuscript.
15
16 32
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2. WHO DATASET

1. **Trial registration:** clinicaltrials.gov, NCT02951338
2. **Date of registration:** 31 October 2016
3. **Secondary identification numbers:** Not applicable
4. **Sources of monetary or material support:** This study is supported by the Canadian Institutes of Health Research (PJT-148906). AM holds a New Investigator Award from the Canadian Institutes of Health Research (MSH-141983). DB holds a Canada Research Chair. AT is supported by a personnel award from the Heart and Stroke Foundation, Ontario Provincial Office (CS I 7468). The views expressed are not necessarily those of the funders.
5. **Primary sponsor:** Avril Mansfield
6. **Secondary sponsors:** Dina Brooks, Ada Tang, Denise Taylor
7. **Contact for public queries:** Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca
8. **Contact for scientific queries:** Avril Mansfield; address: 550 University Ave, Toronto, ON, M5G 2A2; tel: 416-597-3422 ext 7831; e-mail: avril.mansfield@uhn.ca
9. **Public title:** Promoting Optimal Physical Exercise for Life (PROPEL) in people with stroke
10. **Scientific title:** Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: study protocol for a stepped-wedge randomized trial
11. **Countries of recruitment:** Canada
12. **Interventions:** Group aerobic exercise only (Active Comparator): Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal or maximal aerobic capacity test, and a 3-5 minute 'cool-down' of low-intensity exercise. The

1
2 57 choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper,
3
4 58 cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor
5
6 59 recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of
7
8
9 60 perceived exertion, workload, and duration of training will be documented for each session.
10
11 61 These data will be reviewed by the physiotherapist with appropriate progression of the intensity
12
13 62 and/or duration of exercise as necessary. Participants may receive general advice to keep
14
15 63 physically active after discharge, and may receive an individualized home exercise program, as
16
17
18 64 is currently routine care at all sites. PROPEL program (experimental): The PROPEL program
19
20 65 involves both group aerobic exercise (as described above) and group discussion aimed at
21
22 66 enabling participation in exercise after discharge. Components of the PROPEL program were
23
24
25 67 developed according to the Transtheoretical Model of health behaviour change and Social
26
27 68 Cognitive Theory. In addition to group exercise participants will attend 1-hour small group
28
29 69 discussion sessions once weekly to learn self-management skills for exercise in preparation for
30
31
32 70 discharge from rehabilitation. These discussions include: identifying and solving problems
33
34 71 around barriers to exercise; understanding personal and general benefits of exercise; exploring
35
36 72 appropriate community resources for exercise; and finding individualized and realistic strategies
37
38
39 73 for incorporating exercise in a regular routine. Participants will become comfortable with
40
41 74 progressing their exercise and will set short- and long-term goals for engaging in physical
42
43 75 activity and exercise after discharge.

- 45 76 **13. Key inclusion and exclusion criteria:** Inclusion criteria: Adults with stroke who are referred to
47
48 77 the group aerobic exercise or PROPEL programs as part of their stroke rehabilitation. Exclusion
49
50 78 criteria: Language or communication barrier that prevents completion of questionnaires (e.g.,
51
52 79 severe receptive or global aphasia or non-English speaking); cognitive impairment that would
53
54
55 80 prevent participation in unsupervised exercise; attend less than 50% of group aerobic

1
2 81 exercise/PROPEL sessions; and/or attend less than 4 of the 6 group discussion sessions (for
3
4 82 individuals referred to the PROPEL program).
5

6 83 14. **Study type:** Interventional stepped-wedge cluster randomized trial.
7

8
9 84 15. **Date of first enrolment:** February 2017 (anticipated)
10

11 85 16. **Target sample size:** 192
12

13 86 17. **Recruitment status:** Pending: participants are not yet being recruited or enrolled at any site.
14

15
16 87 18. **Primary outcomes:** Number of patients who meet recommended intensity, frequency, and
17
18 88 duration of physical activity; that is, at least 150 minutes per week of moderate-to-vigorous
19
20 89 intensity exercise. Physical activity will be assessed using a step counter, heart rate monitor,
21
22 90 and questionnaire for 7 continuous days at 1-month, 4-months, and 6-months post-discharge.
23
24

25 91 19. **Secondary outcomes:** Short Self-efficacy for Exercise Scale; Short Outcome Expectation for
26
27 92 Exercise Scale; and Barriers to Being Active Quiz
28
29

30 93
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. ABSTRACT

Introduction: Physical exercise after stroke is essential for improving recovery and general health, and reducing future stroke risk. However, people with stroke are not sufficiently active upon return to the community after rehabilitation. We developed the Promoting Optimal Physical Exercise for Life (PROPEL) program, which combines exercise with self-management strategies within rehabilitation to promote ongoing physical activity in the community after rehabilitation. This study aims to evaluate the effect of PROPEL on long-term participation in exercise after discharge from stroke rehabilitation. We hypothesize that individuals who complete PROPEL will be more likely to meet recommended frequency, duration, and intensity of exercise compared to individuals who do not complete the program up to 6-months post-discharge from stroke rehabilitation.

Methods and analysis: Individuals undergoing outpatient stroke rehabilitation at one of 6 hospitals will be recruited (target n=192 total). A stepped wedge design will be employed; i.e., the PROPEL intervention (group exercise plus self-management) will be ‘rolled out’ to each site at a random time within the study period. Prior to roll-out of the PROPEL intervention, sites will complete the control intervention (group aerobic exercise only). Participation in physical activity for 6-months post-discharge will be measured via activity and heart-rate monitors, and standardized physical activity questionnaire. Adherence to exercise guidelines will be evaluated by: 1) number of ‘active minutes’ per week (from the activity monitor); 2) amount of time per week when heart rate is within a target range (i.e., 55-80% of age-predicted maximum); and 3) amount of time per week completing ‘moderate’ or ‘strenuous’ physical activities (from the questionnaire). We will compare the proportion of active and inactive individuals at 6 months post-intervention using mixed-model logistic regression, with fixed effects of time and phase and random effect of cluster (site).

1
2 116 **Ethics and dissemination:** To date, research ethics approval has been received from five of the six
3
4 117 sites, with conditional approval granted by the sixth site. Results will be disseminated directly to study
5
6 118 participants at the end of the trial, and to other stake holders via publication in a peer-reviewed journal.
7
8

9 119

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

4. ARTICLE SUMMARY

- This multi-centre trial will determine if an exercise and self-management intervention can increase participation in physical activity after stroke rehabilitation.
- The novel ‘stepped wedge’ trial design is suitable given the group-based delivery of the intervention and relatively small number of sites involved.
- Participation in physical activity will be determined with three methods: self-report (activity questionnaire), daily heart rate monitoring, and daily activity monitoring.
- The trial is single-blinded (participants cannot be blinded to intervention allocation), which potentially introduces a source of bias.

5. INTRODUCTION

5.1 Background and rationale

People often have low aerobic capacity after stroke,^{1 2} which can limit the stroke survivors' ability to complete activities of daily living.^{1 3 4} Aerobic exercise is beneficial post-stroke for improving aerobic capacity,⁵⁻⁷ maintaining or promoting recovery⁸ and for general health, including reducing risk of another stroke or other cardiovascular events.⁹ Indeed, aerobic exercise is beneficial and feasible even early after stroke and during routine rehabilitation^{6 10} However, due to the brief length of stay in stroke rehabilitation (4-6 weeks), ongoing self-directed physical activity post-discharge is necessary to maintain these benefits.

People with stroke do not maintain adequate levels of long-term exercise. Community-living people with stroke walk, on average, 70 to 5800 steps/day,¹¹ which is less than the 6000 steps/day recommended for people with physical disabilities.¹² Data from heart rate monitors revealed that, even when individuals with stroke were active, the activity was not of sufficient intensity for aerobic benefit.¹³ This chronic inactivity means that gains in aerobic fitness made during rehabilitation will be lost post-discharge.¹⁴

There is a need to establish strategies to promote long-term uptake of exercise after stroke.¹⁵ Most studies aiming to increase self-directed exercise post-stroke have been implemented in the community after formal rehabilitation is complete.^{16 17} While some community-based programs have reported increased physical activity after the program,¹⁸⁻²⁰ many people have difficulty accessing community programs¹⁶ and consequently attendance can be low.²¹ The early recovery period during rehabilitation may be an optimal time to not only deliver fitness programming to increase exercise capacity, but also to shape long-term self-directed exercise behaviour.¹⁴ To our knowledge only one group has studied such a program during stroke rehabilitation.²² This study found that 67% of those who completed the intervention met exercise recommendations, compared to 55% in the control group.

1
2 154 However, this study was limited by a non-randomized design, high rates of withdrawal in the
3
4 155 intervention group compared to the control group (28% versus 12%), and low rates of compliance with
5
6 156 the intervention (<67%). Furthermore, this study included individuals receiving rehabilitation for
7
8
9 157 various conditions and was not focused solely on people with stroke, who have unique challenges to
10
11 158 participating in exercise.²³

13 159 We developed Promoting Optimal Physical Exercise for Life (PROPEL) – a combined group
14
15
16 160 exercise and self-management program that aims to promote long-term engagement in exercise and
17
18 161 physical activity after stroke. Our pilot non-randomized study suggests that those who complete
19
20 162 PROPEL are more physically active after discharge from rehabilitation than those who do not.²⁴

25 164 **5.2 Objectives**

27 165 The primary aim of this study is to evaluate the effect of PROPEL delivered during stroke
28
29
30 166 rehabilitation on participation in self-directed exercise after rehabilitation. Our secondary aims are to
31
32 167 evaluate the effect of PROPEL on self-efficacy and outcome expectations for exercise, and barriers to
33
34 168 exercise. We hypothesize that, compared to those who complete group aerobic exercise only, those
35
36 169 who complete PROPEL will: 1) be more likely to meet the recommended intensity and duration of self-
37
38
39 170 directed physical activity in the community (i.e., ≥ 150 mins/week of moderate intensity exercise²⁵); and
40
41 171 2) report higher self-efficacy and outcome expectations for exercise, and fewer barriers to community
42
43 172 activity.

48 174 **5.3 Trial design**

50 175 This study involves a single-blind (assessor blinded), continuous recruitment short exposure, stepped-
51
52 176 wedge cluster randomized controlled superiority trial (SWT).²⁶ Six sites will be involved in the study;
53
54
55 177 at a randomly-determined time within the study period (Figure 1), each site will transition from the

1
2 178 control intervention (group aerobic exercise only; GAE) to the experimental intervention (PROPEL).
3
4 179 New participants will be recruited continuously throughout the study period and will either complete
5
6 180 the GAE or PROPEL intervention, depending on which program that site is administering at the time at
7
8
9 181 which they are admitted to rehabilitation.
10

11 182 The group format is essential to PROPEL (see below). In our pilot study²⁴ there was often a
12
13 183 delay to start the group in order to have ≥ 3 people enrolled. Therefore, a study design whereby
14
15 184 individual participants are randomly allocated to either GAE or PROPEL would be problematic as
16
17
18 185 there would be even greater delays in starting the groups since twice as many people would be required
19
20 186 to be enrolled in order to run concurrent groups. Likewise, a traditional cluster randomized controlled
21
22
23 187 trial, where sites are randomly assigned to either complete GAE or PROPEL, would not be ideal due to
24
25 188 the relatively low number of sites (6), and thus, reduced statistical power.²⁷ Therefore, the SWT is a
26
27 189 pragmatic trial design that is suitable for evaluating interventions that are implemented routinely at the
28
29 190 level of cluster.^{26 27} It balances the need for robust evaluation with logistic constraints in program
30
31
32 191 evaluation, particularly in cases of inter-site variability.²⁸ Indeed, previous authors have argued that
33
34 192 well-designed and executed SWTs can be as rigorous as traditional cluster randomized trials.²⁶
35
36
37 193

38 39 194 **6. METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES**

40 41 195 **6.1 Study setting**

42
43 196 Participants will be recruited from one of 6 rehabilitation hospitals in Ontario: 1) Hamilton Health
44
45 197 Sciences, Hamilton, Ontario; 2) St. Joseph's Care Group, Thunder Bay, Ontario; 3) Sunnybrook Health
46
47
48 198 Sciences Centre – St. John's Rehab, Toronto, Ontario; 4) Toronto Rehabilitation Institute – Rumsey
49
50 199 Centre, Toronto, Ontario; 5) Toronto Rehabilitation Institute – University Centre, Toronto, Ontario;
51
52 200 and 6) West Park Healthcare Centre, Toronto, Ontario. Each site will be staffed by a research assistant
53
54
55
56
57
58
59
60

1
2 201 (RA) and a physiotherapist (PT). The RA will be responsible for recruiting participants and collecting
3
4 202 data. The PT will administer the interventions.
5

6 203 7 8 9 204 **6.2 Eligibility criteria**

10
11 205 Individuals who complete either GAE or PROPEL as part of routine care at one of the 6 sites will be
12
13 206 invited to participate in the study. To be eligible for referral to GAE or PROPEL, patients must be
14
15 207 admitted to the facility for rehabilitation after a diagnosed stroke, and must have sufficient cognitive
16
17
18 208 capacity to understand and follow instructions and to convey adverse symptoms with exercise (e.g.,
19
20 209 pain, excessive exertion). Patients will be excluded from GAE or PROPEL if they have conditions that
21
22 210 limit their ability to exercise, including uncontrolled hypertension, uncontrolled diabetes, other
23
24
25 211 cardiovascular morbidity that limits exercise tolerance (e.g., heart failure, abnormal blood pressure
26
27 212 responses or ST-segment depression >2mm, symptomatic aortic stenosis, or complex arrhythmias),
28
29
30 213 unstable angina, orthostatic blood pressure decrease of >20mmHg, or musculoskeletal impairments or
31
32 214 pain. Additionally, participants will be withdrawn from GAE or PROPEL if significant cardiovascular
33
34 215 abnormalities are observed during the sub-maximal exercise test. We have used these criteria to
35
36 216 successfully enrol patients with stroke in aerobic exercise during in-patient rehabilitation with no
37
38
39 217 serious adverse events.¹⁰ Referral to the group will be made by the patients' primary treating
40
41 218 physiotherapists, who will document the patients' verbal consent for treatment, as is usual practice.
42

43 219 Patients will be screened for eligibility for the study within the final two weeks of the
44
45 220 GAE/PROPEL programs. Participants will be considered for inclusion in the study if they are referred
46
47
48 221 to the GAE or PROPEL program as part of their stroke rehabilitation. Participants will be excluded
49
50 222 from the study if:

- 51
52 223 • They have a language or communication barrier that prevents completion of
53
54
55 224 questionnaires (e.g., severe receptive or global aphasia or non-English speaking);
56
57
58
59
60

- 1
- 2 225 • They have cognitive impairment that would prevent participation in unsupervised
- 3
- 4 226 exercise;
- 5
- 6
- 7 227 • They attend less than 9 group exercise sessions; and/or
- 8
- 9 228 • They attend less than 4 of the 6 group discussion sessions (for individuals enrolled in the
- 10
- 11 229 PROPEL program).
- 12

13
14 230 Communication and cognitive capacity to participate in the study will be determined via consultation
15
16 231 with participants' healthcare team.

18 232 19 20 233 **6.3 Interventions**

22
23 234 The interventions will be implemented as part of routine care at all sites according to the schedule
24
25 235 outlined in Figure 1 (e.g., Site B is expected to implement GAE in mid-February 2017, and PROPEL in
26
27 236 around mid-May 2017). The interventions will supplement, rather than replace, current practice; that is,
28
29
30 237 patients will still complete their regularly-scheduled physiotherapy, occupational therapy, and speech
31
32 238 and language pathology sessions, as required. However, for patients who are enrolled in the GAE or
33
34 239 PROPEL interventions, physiotherapists might choose not to complete individualized aerobic exercise
35
36
37 240 during patients' regularly scheduled physiotherapy sessions as this will be completed as part of
38
39 241 GAE/PROPEL, and to spend this time instead focusing on other rehabilitation goals (e.g., balance or
40
41 242 gait retraining).

43
44 243 Both interventions involve supervised, individualized, group aerobic exercise 3 days/week for 6
45
46 244 weeks informed by a sub-maximal or maximal aerobic capacity test. Patients will be referred by their
47
48 245 treating physiotherapist. The interventions will be delivered in a 'closed group' format. That is,
49
50
51 246 participants referred to the program will be placed on a waiting list until there are a sufficient number
52
53 247 of participants to form a group (≥ 3), and all participants in the group will start and end the program at
54
55 248 the same time. The closed-group format is essential for the PROPEL phase as the education and group
56
57
58
59
60

1
2 249 discussion topics will be presented in a specific order. An open-group format could be used for GAE;
3
4 250 however, this would result in participants in the GAE phase being recruited to the study, on average,
5
6 251 sooner post-stroke than those in the PROPEL phase.²⁴ Therefore, using a closed-group format for both
7
8
9 252 phases will help to ensure that the mean time post-stroke at study enrolment does not differ between the
10
11 253 two phases of intervention. Prior to starting the group, participants may complete individualized or
12
13 254 open-group aerobic exercise as part of their regular in- or out-patient rehabilitation.

15
16 255 PTs at each site will receive training in sub-maximal aerobic capacity testing for individuals
17
18 256 with stroke, exercise prescription, and leading the PROPEL program from the study investigators (ELI,
19
20 257 LB, CJD, and AT).

25 259 *6.3.1 Control intervention – GAE*

27 260 The control intervention will involve group aerobic exercise only (GAE). The intensity and duration of
28
29 261 exercise will be determined for each individual patient from the results of a sub-maximal or maximal
30
31 262 aerobic capacity test conducted prior to entry into the program, and considering patients' medical
32
33 263 history and stroke-related impairments.¹⁰ In general, the duration of exercise will be 20-30 minutes, and
34
35 264 the intensity will be 50-70% of age-predicted maximum heart rate or a rating of 3/10 ('moderate') on
36
37 265 the Borg category ratio (CR-10) scale.²⁹ The choice of exercise modality for the submaximal test and
38
39 266 for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed
40
41 267 based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Group
42
43 268 exercise will be supervised by the PT. Each exercise session will begin with a 3-5 minute 'warm-up',
44
45 269 and end with a 3-5 minute 'cool-down' of low-intensity exercise. Heart rate, blood pressure, rate of
46
47 270 perceived exertion, workload, and duration of training will be documented for each session. These data
48
49 271 will be reviewed by the PT with appropriate progression of the intensity and/or duration of exercise as
50
51 272 necessary.
52
53
54
55
56
57
58
59
60

1
2 273 Patients in the GAE program may receive general advice to keep physically active after
3
4 274 discharge, and may receive an individualized home exercise program, as is currently routine care at all
5
6 275 sites.

8
9 276

11 277 *6.3.2 Experimental intervention – PROPEL*

12
13 278 The PROPEL program,²⁴ involves both group aerobic exercise and group discussion aimed at enabling
14
15
16 279 participation in exercise after discharge. Components of the PROPEL program were developed
17
18 280 according to the Transtheoretical Model of health behaviour change³⁰ and Social Cognitive Theory.³¹
19
20 281 Participants will complete group exercise 3 days/week (described above for GAE). Additionally,
21
22 282 participants will also attend 1-hour small group discussion sessions once weekly to learn self-
23
24 283 management skills for exercise in preparation for discharge from rehabilitation. Specific objectives of
25
26 284 the discussion sessions are to: 1) increase participant knowledge regarding the benefits of exercise and
27
28 285 physical activity after stroke; 2) build participant skill and self-efficacy for exercise; and 3) establish a
29
30 286 feasible post-discharge exercise plan. Through interactive discussions, individualized problem solving,
31
32 287 and goal setting, the following topics will be addressed, such that a feasible personal exercise plan is
33
34 288 iteratively developed:

- 35
36 289 • Risks and benefits of exercise;
- 37
38 290 • Current guidelines and recommendations for exercise;
- 39
40 291 • Personal barriers to and preferences for exercise;
- 41
42 292 • Components of an exercise prescription (i.e., frequency, intensity, type and time);
- 43
44 293 • How to monitor exercise intensity (e.g., using heart rate and rating of perceived exertion);
- 45
46 294 • How to progress an exercise program;
- 47
48 295 • How to set short- and long-term goals;
- 49
50 296 • Strategies to sustain and/or re-engage in exercise;

51
52
53
54
55
56
57
58
59
60

1
2 297 Additionally, individuals are encouraged to identify and trial appropriate community resources for
3
4 298 exercise, and find individualized and realistic strategies for incorporating exercise in a regular routine.
5
6 299 The group format helps to promote vicarious experiences. The PROPEL discussions will be led by the
7
8
9 300 PT; access to a health care professional leading the group can increase an individual's belief about
10
11 301 personal skill,³² and support in teaching stroke survivors how to exercise independently, promoting
12
13 302 feelings of safety and confidence.^{33 34}
14
15

18 304 **6.4 Outcomes**

20 305 *6.4.1 Primary outcomes – physical activity*

22 306 Physical activity will be assessed using a step counter and heart rate monitor for 7 continuous days, as
23
24
25 307 well as a physical activity questionnaire at three time points: 1) one month, 2) four months, and 3) six
26
27 308 months post-intervention (Figure 2). Because of the limitations of relying on a single method of data
28
29 309 collection for physical activity data, combining data from these three sources is recommended.^{13 23 24 35}
30
31
32 310 Participants will be supplied with a commercial wrist-worn step counter and heart rate monitor (FitBit
33
34 311 Charge HR). Our pilot data suggest that this device provides reasonably accurate measures of walking
35
36 312 activity and heart rate among individuals with stroke (unpublished data). Individuals who typically use
37
38
39 313 a rollator for ambulation may also be provided with an activity monitor to be worn at the ankle (FitBit
40
41 314 One), which would be more accurate for measuring walking activity than a wrist-worn device for these
42
43 315 individuals.³⁶ The devices will be configured to not provide participants with information regarding
44
45
46 316 step counts and heart rate. The devices will be mailed to participants with a postage-paid return
47
48 317 envelope. Participants will be instructed to wear the device at all times (except when bathing) for 7
49
50 318 days continuously.

52 319 The Physical Activity Scale for Individuals with Physical Disabilities (PASIPD)³⁷ will be
53
54
55 320 conducted by telephone with a blinded RA at the end of the 7-day monitoring period. The PASIPD is a
56
57
58
59
60

1
2 321 13-item questionnaire in which participants are asked to indicate the frequency and duration of
3
4 322 recreational, household and occupational physical activities completed in the previous 7 days. The
5
6 323 PASID has been validated within a group of individuals with various physical disabilities, including
7
8
9 324 individuals with stroke, showing good test-retest reliability ($\rho=0.77$) and criterion validity when
10
11 325 compared to accelerometer-based activity monitoring ($\rho=0.30$).³⁸

12
13
14 326 We will use the step activity, heart rate, and questionnaire data to determine if participants meet
15
16 327 the recommended intensity and duration of physical activity in the community; that is, at least 150
17
18 328 minutes per week of moderate-vigorous intensity exercise.²⁵ Participants will be deemed to meet the
19
20 329 recommendations within a given week if they meet at least two of three criteria: 1) record at least 150
21
22 330 'active minutes' (from the step activity monitor); 2) record at least 150 minutes of heart rate between
23
24 331 55-80% of age-predicted maximum;⁹ and/or 3) report at least 150 minutes of moderate and/or vigorous
25
26 332 intensity activity on the PASIPD.

32 334 *6.4.2 Secondary outcomes - self-efficacy and outcome expectations for exercise, and barriers to activity*

33
34 335 Exercise self-efficacy will be assessed using the Short Self-Efficacy for Exercise (SSEE) scale.³⁹ The
35
36 336 SSEE is a four-item questionnaire where participants are required to rate their confidence exercising
37
38 337 through pain and fatigue, and when alone and depressed on a five-point scale. The Short Outcome
39
40 338 Expectation for Exercise (SOEE) scale³⁹ will be used to assess beliefs and attitudes related to exercise.
41
42 339 The SOEE is a five-item questionnaire where participants are asked to rate their beliefs regarding the
43
44 340 benefits of exercise on a five-point scale. The SSEE and SOEE will be assessed at enrolment into the
45
46 341 study. The SSEE and SOEE have been shown to be valid and reliable among individuals with chronic
47
48 342 stroke.³⁹

49
50
51 343 Perceived barriers to physical activity will be assessed 1-month post-intervention with the
52
53 344 Barriers to Being Active Quiz (BBAQ).^{23 40 41} The BBAQ has previously been used to evaluate barriers

1
2 345 to exercise among individuals with stroke.²³ The BBAQ is a 21-item scale where individuals are
3
4 346 required to indicate how likely they are to make specific statements regarding barriers to exercise, for
5
6 347 example “I’m getting older so exercise can be risky”.⁴⁰ Items on seven categories of barriers are
7
8
9 348 included in the questionnaire: lack of time, social influence, lack of energy, lack of willpower, fear of
10
11 349 injury, lack of skill, and lack of resources. Each individual item is scored from 0-3 and scores for each
12
13 350 barrier category are the sum of the scores for the three items in that category. Participants are
14
15
16 351 considered to have a ‘significant’ barrier to being active if the score for a category is 5 or higher.²³ The
17
18 352 average number of significant barriers per participant will be calculated. The BBAQ has good internal
19
20 353 consistency among older adults (Cronbach’s $\alpha=0.87$).⁴²
21
22
23 354

25 355 *6.4.3 Cohort descriptors*

27 356 The following information will be obtained from chart review in order to characterize individuals who
28
29
30 357 participate in the study: age, sex, time post-stroke (at enrolment into the study), lesion location,
31
32 358 mobility status, and medical conditions/history. The National Institutes of Health Stroke Scale (NIH-
33
34 359 SS),⁴³ the Chedoke-McMaster Stroke Assessment (CMSA)⁴⁴ foot and leg scores, and the Montreal
35
36 360 Cognitive Assessment⁴⁵ will be administered at enrolment into the study by the RA or study PT;
37
38
39 361 however, if these measures were conducted as part of clinical care within 1-week of study enrolment,
40
41 362 the scores will be extracted from the hospital charts to minimize participant burden. The NIH-SS is an
42
43 363 11-item scale that provides a gross measure of the effects and severity of stroke. The NIH-SS has good
44
45
46 364 intra-rater (ICCs=0.93) and inter-rater (ICCs=0.95) reliability.⁴⁶ The CMSA assigns a score according
47
48 365 to the level of motor recovery in the foot and leg and is frequently used to evaluate level of motor
49
50 366 recovery post-stroke in clinical settings. The CMSA foot and leg scores have good intra-rater
51
52
53 367 (ICCs=0.94-0.98) and inter-rater (ICCs=0.85-0.96) reliability.⁴⁴ The MOCA⁴⁵ is a paper-based test that
54
55
56
57
58
59
60

1
2 368 can be used to screen for mild cognitive impairment; patients are scored on visuospatial and executive
3
4 369 function, naming, memory, attention, language, abstraction, delayed recall, and orientation.
5

6 370 We will document the frequency, intensity, and duration of exercise during in- and out-patient
7
8
9 371 rehabilitation by chart review. We will also document details of any home exercise program or general
10
11 372 advice to be physically active that participants receive (outside of the PROPEL intervention).
12

13 373 Participants will complete a questionnaire at baseline that asks about their social supports, employment,
14
15 374 familial responsibilities, living situation etc, which are factors that could influence participation in
16
17
18 375 physical activity. Many of these questions have been adapted from the Canadian Longitudinal Study on
19
20 376 Aging.⁴⁷ Some questions will be repeated at the 6-month post-discharge time-point to account for
21
22 377 lifestyle changes since discharge from rehabilitation. Pre-morbid exercise behaviour will be evaluated
23
24
25 378 with the Schmidt retrospective physical activity scale.⁴⁸ This scale shows good agreement with
26
27 379 previously-completed questionnaires regarding physical activity.⁴⁸ We will use this scale to estimate
28
29 380 participants' average amount of time (hours/day) prior to their strokes spent in sedentary activities
30
31
32 381 (e.g., watching television, sedentary occupational activity) and in physical recreational activity or
33
34 382 exercise.
35

36 383 37 38 39 384 **6.4 Sample size**

40
41 385 We expect that approximately 25% of people who complete GAE⁴⁹ and 50% of individuals who
42
43 386 complete PROPEL²⁴ will be classified as 'active'. A sample of 96 per phase will provide 80% power to
44
45 387 detect a 25% to 50% difference at alpha of 0.05 for the 6 sites taking into account an intracluster
46
47
48 388 correlation of 0.05.⁵⁰ The sample size calculation was run using PASS Version 12 (Hintze, J, 2014,
49
50 389 NCSS, LLC. Kaysville, Utah). We will aim to recruit 120 participants total per phase to account for a
51
52 390 conservative 20% drop-out rate.
53
54
55 391
56
57
58
59
60

6.5 Recruitment

There are approximately 710 admissions annually to out-patient stroke rehabilitation at all sites combined. We conservatively estimate that 40% of these individuals will be eligible for the study and, of these, 50% will consent to participate. Thus, we expect to recruit ~140 participants annually to meet the target sample size with ~2 years of recruiting. Target sample sizes for each site are: Hamilton Health Sciences – 24; St Joseph’s Care Group – 24; Sunnybrook Research Institute - St John’s Rehab – 60, Toronto Rehabilitation Institute – Rumsey Centre – 58, Toronto Rehabilitation Institute – University Centre – 58, West Park Healthcare Centre – 60. To encourage recruitment to the study, participants will receive a gift card (\$30 CAD value) as a modest incentive to participate.

In order to generate a CONSORT flow-diagram for participant recruiting,⁵¹ RA will count the number of individuals who are admitted to the out-patient stroke program and, of these, the number who are referred to the GAE or PROPEL program. The RA will also maintain documentation related to screening and enrolment of potential participants. Identifying or health-related information will not be documented for individuals who do not consent to participate in the study.

7. METHODS: ASSIGNMENT OF INTERVENTIONS

7.1 Intervention allocation

The time at which each site transitions from GAE to PROPEL will be determined by drawing site names at random (Figure 1). One site will implement PROPEL at the start of the study period, whereas one site will never transition to PROPEL; this will help to ensure blinding of assessors (see Section 7.2). The site that does not transition to PROPEL during the study period will be offered training in PROPEL at the end of the study period. Intervention allocation will be performed at the start of the study period by the Principal Investigator, who will not be directly involved in recruiting or data

1
2 415 collection. The Site Leads and PTs at each site will be informed of the transition to PROPEL
3
4 416 approximately 3 months prior to the transition to allow for sufficient time for training and planning.
5

6 417
7

8 418 **7.2 Blinding**

10
11 419 Participants cannot be blinded to intervention allocation, although they will not be aware of the
12
13 420 existence of another intervention arm. Assessors (RA at each site) who collect data, including
14
15 421 administering questionnaires, will be unaware of the time at which the site transitions from GAE to
16
17 422 PROPEL. While it is more likely that a given site will be allocated to GAE at the start of the study
18
19 423 period, and to PROPEL at the end of the study, inclusion of two sites that always complete either GAE
20
21 424 or PROPEL will create uncertainty in intervention allocation at all time points. Furthermore, using
22
23 425 objective methods to collect data pertaining to the primary outcome (i.e., heart rate and activity
24
25 426 monitor) helps to protect against bias if assessors inadvertently become unblinded.
26
27 427
28

29 428 **8. METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS**

30 429 **8.1 Data collection methods**

31
32 430 Data will be collected primarily by the RA either directly from the participant or by chart review (see
33
34 431 Table 1 for further details). RAs at each site will receive training regarding data collection from the
35
36 432 Principal Investigator (AM) and central Study Coordinator (AA). Questionnaires will be completed via
37
38 433 in person interview at enrolment, and over the telephone at the follow-up time points. Activity monitors
39
40 434 will be sent to participants and returned to the site via mail. Participants will be contacted via telephone
41
42 435 just prior to mailing the activity monitors to remind them that they will be receiving the activity
43
44 436 monitors, and to ensure that they will be home to receive them (e.g., that they are not planning to be on
45
46 437 vacation at that time).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 438 In order avoid losing participants to follow-up, we will request contact information of a friend
3
4 439 or family member. Participants who provide consent for us to contact their friends or family members
5
6 440 will be provided with a contact form at the time when written consent is obtained, and will be asked to
7
8
9 441 return the form at the next visit or by mail (a stamped self-addressed envelope will be provided). This
10
11 442 information will only be used to obtain information about the whereabouts of a research participant if
12
13 443 we are unable to contact them after multiple attempts. Participants will primarily be contacted by
14
15
16 444 telephone throughout the study, unless otherwise requested. Each time they are contacted, participants
17
18 445 will be told when they should next expect to hear from the RA and will be asked to inform the RA of
19
20 446 upcoming limited availability (e.g. due to vacation or scheduled surgery). A letter will be mailed to
21
22
23 447 participants who are unable to be reached: 1) because his/her telephone number is out of service; or 2)
24
25 448 five attempts have been made to telephone the participant over the course of two weeks (with at least
26
27 449 two voicemail messages for participants who have voicemail and have provided consent for us to leave
28
29
30 450 voicemail). In the latter case, telephone calls will be placed at varying times of the day in an attempt to
31
32 451 reach participants who are unavailable at the same time each day due to regular appointments. The
33
34 452 letter will request that participants contact the RA. If the RA does not hear from the participant two
35
36 453 weeks after the letter was mailed, the RA will contact the alternative contact.
37
38
39 454

41 455 **8.2 Data management**

42
43 456 Each activity monitor will be linked to an anonymous account and activity monitor data will be stored
44
45
46 457 on the manufacturer's servers linked to these anonymous accounts. We will document internally which
47
48 458 participants' data are associated with which accounts; therefore, there will be no information about
49
50 459 study participants (e.g., name, age, study ID number) stored on the manufacturer's servers. Activity
51
52
53 460 data will be downloaded from the manufacturer's servers as soon as possible after collection. All other
54
55 461 electronic data will be stored at each site on secure institutional servers. Files containing patient names
56
57
58
59
60

1
2 462 and contact information will be password protected and stored separately from other data. Hard copies
3
4 463 of files containing de-identified data will be stored in locked cabinets and/or in offices that are locked
5
6 464 when not occupied. Consent forms will be stored in locked cabinets/offices separately from other data.
7
8
9 465 Only those individuals who require access to the data for the purpose of this study will be provided
10
11 466 with the password to the file containing identifiers and/or the keys to the locked cabinet/office. De-
12
13 467 identified electronic data will be transferred to the main site (Sunnybrook Research Institute) using
14
15
16 468 secure file transfer protocols.
17

18 469 19 20 470 **8.3 Statistical analysis**

21
22 471 We will compare cohort descriptors between the two phases (GAE and PROPEL) using t-tests, Mann-
23
24
25 472 Whitney *U* tests, or chi-square tests, as appropriate. If phases significantly differ at baseline on cohort
26
27 473 descriptors, these measures may be used as covariates in the analysis. To test our primary hypothesis,
28
29
30 474 we will compare the proportion of active and inactive individuals at the final assessment point (6
31
32 475 months post-intervention) using mixed-model logistic regression, with fixed effects of time and phase
33
34 476 and random effect of cluster (site).⁵² We will also examine between-phase differences in physical
35
36 477 activity at the 1-month and 4-month time points, which could reveal short-term benefits of PROPEL,
37
38
39 478 even if there are no differences at 6-months. A similar mixed-model ANOVA will be used to compare
40
41 479 SSEE, SOEE, and BBAQ scores between programs to test the secondary hypotheses. Only individuals
42
43 480 who complete at least a minimum amount of the intervention will be included in the study; therefore,
44
45
46 481 analysis will necessarily be ‘per protocol’. All recruited participants who comply with data collection
47
48 482 will be included in the analysis; participants with missing data for one time point will be excluded from
49
50 483 analysis of that variable for that time point.
51

52 484 53 54 55 485 **9. METHODS: MONITORING**

56
57
58
59
60

9.1 Data monitoring

There is no data monitoring committee for this study, as the safety of aerobic exercise has already been established for this population,^{6 10} and the additional risk of the discussion components of the PROPEL program and other study components (e.g., questionnaires or activity monitoring) is minimal (see Section 9.2). Adverse events that meet all three of the following criteria will be reported immediately to the local research ethics board(s), as is routine practice: 1) unexpected in terms of nature, severity, or frequency; 2) related or possibly related to participation in the research; and 3) suggests an potential increase in risk of harm to research participants or to others. All adverse events will be collated and evaluated bi-annually by the Principal Investigator (AM).

There is no plan for any interim analysis; interim analysis is not feasible with a SWT design due to the fact that the experimental intervention is ‘rolled out’ gradually to each site, which means that the number of participants per phase will be uneven until the end of the trial. The trial will be stopped when one of the following criteria are met: 1) we have recruited at least 120 participants per phase; 2) 6-month follow-up data are available for at least 96 participants per phase; or 3) all site investigators (AM, DB, AT, and DT) agree that continuing the trial will not be feasible (e.g., due to lower than expected recruiting and lack of funding to continue the trial).

9.2 Potential harms and auditing

Sites will implement two interventions as part of routine care (GAE or PROPEL). Some aerobic exercise is currently conducted at all sites, but might not be implemented in the systematic manner required for this study. However, aerobic exercise is recommended as part of stroke rehabilitation within the Canadian Stroke Best Practice Recommendations.⁵³ Furthermore, with appropriate screening and prescription, aerobic exercise is safe and feasible early after stroke.¹⁰ Treating physiotherapists will screen patients, with appropriate consultation with the inter-professional team, and provide the exercise

1
2 510 prescription following established guidelines for aerobic exercise after stroke,⁵⁴ prior to referring them
3
4 511 to GAE or PROPEL. Heart rate and blood pressure will be measured at rest at the start of each
5
6 512 intervention session to obtain a baseline measure of cardiovascular function. The interventions will be
7
8
9 513 supervised by a trained registered physiotherapist, who will continue to monitor patients' response to
10
11 514 exercise and may choose to adjust the intensity or duration of exercise to minimize risk to participants.
12

13 515 The Canadian Stroke Best Practice Recommendations also recommend including a plan to
14
15 516 enable patients to continue to exercise post-discharge, including addressing barriers to physical
16
17
18 517 activity.⁵³ However, the specific education, self-management, and problem-solving components of the
19
20 518 PROPEL program are not part of routine care at all sites. The additional risk to participants in
21
22 519 completing this component of the PROPEL program is minimal. Participants can opt out of any part of
23
24
25 520 the discussion if they feel uncomfortable.
26

27 521 The additional measures conducted as part of the study pose minimal risk to participants. The
28
29 522 CMSA, NIH-SS, and MOCA are frequently conducted as part of clinical care in stroke rehabilitation.
30
31
32 523 Other measures are questionnaires which ask routine questions about physical activity behaviour and
33
34 524 lifestyle. Despite the minimal risk involved in these measures, participants will be reminded that they
35
36 525 can opt out of any testing and/or decline to answer any of the questions in the questionnaires. The
37
38
39 526 activity monitoring also poses minimal risk to participants; the devices are available commercially and
40
41 527 are worn daily by millions of individuals around the world. Participants may develop skin irritation
42
43 528 from wearing the device daily; they will be instructed to remove the device if this occurs. Participants
44
45 529 may feel burdened by donning and doffing the activity monitors each day.
46
47

48 530 The study PT will document any adverse events that occur during the interventions; the RA will
49
50 531 document adverse events for participants who enrol in the study during the follow-up period.
51
52
53 532

54 55 533 **10. ETHICS AND DISSEMINATION** 56 57 58 59 60

10.1 Research ethics approval

Research ethics approval has been received by the Research Ethics Boards of Sunnybrook Research Institute (Study ID: 472-2016, approved 31 January 2017), the University Health Network (Study ID: 16-5916, approved 14 November 2016), which covers two sites (Toronto Rehabilitation Institute – University Centre, and Toronto Rehabilitation Institute – Rumsey Centre), St. Joseph’s Care Group (Study ID: 2016011, approved 13 February 2017), and Hamilton Health Sciences (Study ID: 2274, approved 6 April 2017). Additionally, conditional approval has been granted by the Joint West Park Healthcare Centre-Toronto Central CCAC-Toronto Grace Health Centre Research Ethics Board, pending some clarifications in the protocol and minor site-specific edits to the consent documents (conditional approval: 20 April 2017). Due to one investigator’s affiliation, research ethics approval was also received from Thunder Bay Regional Health Sciences Centre (Study ID: 2016139, approved 4 January 2017), although no recruiting or data collection will occur at this site.

10.2 Protocol amendments

Substantive changes to the design or conduct of the study will require a formal amendment to the study protocol. Such substantive amendments will be agreed upon by the site investigators (AM, DB, AT and DT) and will be approved by the local Research Ethics Boards prior to implementation locally. Minor administrative changes to study documents (e.g., correcting a typographical error or clarifying a questionnaire item) may also be implemented, with the Research Ethics Boards notified of the changes.

10.3 Consent

Potential participants will be assessed for eligibility by the study PT within the final two weeks of the patients’ participation in the GAE/PROPEL programs. The study PT, who is in the patients’ circle of care, will ask eligible patients if they are interested in speaking with the RA about participating in the

1
2 558 study. The RA will discuss the study at a time that is convenient for interested individuals. S/he will
3
4 559 describe the study, as outlined in the consent form (Appendix) and will answer any questions the
5
6 560 patient may have about the study. The patient will be provided with a copy of the consent form and will
7
8
9 561 be invited to discuss the study with friends or family members, and/or to take some time to think about
10
11 562 being involved in the study. If a patient indicates that s/he would like to participate in the study, s/he
12
13 563 will be asked to sign the consent form. At that time, the RA will arrange a time that is convenient for
14
15
16 564 the participant to collect baseline data (see Section 6.4.3). We will assume that patients who do not
17
18 565 provide consent to the study within two weeks after they finish the GAE/PROPEL program are not
19
20 566 interested in participating in the study.
21
22

23 567 24 25 568 **10.4 Confidentiality**

26
27 569 The study PT will run the GAE and PROPEL interventions as part of routine care at each site. Patients
28
29
30 570 who are referred to GAE or PROPEL may decline participation in the study. Therefore, individuals
31
32 571 who do not consent to the study may participate in GAE or PROPEL. The study PT will be an
33
34 572 individual who also has a role in clinical care on the stroke program at the site and, therefore, will
35
36 573 already be part of the circle of care. The study PT will not have a role in recruiting participants into the
37
38
39 574 study, other than to introduce the study and, if interested, introduce the RA to potential participants.
40

41 575 Identifiable information (participant names and contact information) will be stored separately
42
43 576 from health information and study data (see also Section 8.2) in a password protected file, with the
44
45
46 577 password only known to those individuals who are responsible for data collection. A participant ID
47
48 578 number will be used to link identifiable information with health information and study data. The link
49
50 579 between the participant ID number and name will be destroyed after data have been collected and
51
52
53 580 verified. De-identified data will be kept in a secure and confidential location for 10 years.
54
55 581

10.5 Declaration of interests

The authors declare that they have no competing interests related to this study.

10.6 Access to data

The Principal Investigator (AM) and biostatistician (AK) will have access to the full dataset. The site investigators will have access to data collected locally. A study co-investigator or collaborator may be granted access to the full dataset for secondary analysis with approval of all site investigators (AM, DB, AT, and DT) and the coordinating institution (Sunnybrook Research Institute).

10.7 Ancillary and post-trial care

Each site will be responsible for providing out-of-pocket expenses to ensure that a participant receives immediate medical care in the event that the participant experiences an adverse health event (e.g. injury) as a result of participation in the study.

10.8 Dissemination policy

Study participants will receive a letter of appreciation at the end of the study, which may include a very brief summary of the study results. Study results will be disseminated to others via publication in a peer-reviewed journal. We will aim to submit a paper describing analysis of the primary and secondary outcomes within 6 months of completing data collection. All individuals who meet the International Committee of Medical Journal Editors criteria for authorship will be included as authors on any publications arising from this work. There is no current plan to make the participant-level dataset available publicly; however, the dataset may be made available in future via a Data Access Committee, if such a committee is established by the coordinating institution.

11. STUDY STRENGTHS AND LIMITATIONS

We have adopted an ‘integrated knowledge translation’ approach, whereby knowledge users (rehabilitation managers and physiotherapists) have been involved in the study from conception. The interventions are being implemented as part of routine care at each site. This also helps to increase the likelihood that the interventions will continue as part of routine care beyond the end of the study, compared to implementing the interventions for study participants only.

The novel ‘stepped wedge’ trial design is appropriate for evaluating the group-based PROPEL intervention as it is ‘rolled out’ as part of routine practice to each site.²⁷ However, it is possible that factors that change over time will influence the study results. For example, stroke rehabilitation delivery in Ontario is supported by the Ministry of Health and Long-Term Care through the Ontario Health Insurance Program. During the course of the study, it is possible that the Ministry will dictate changes to care delivery, such as changes to lengths of stay. However, ‘vertical’ comparisons between sites can be made at any point in time to account for such secular trends.^{52 55} An alternative approach would be to have some sites start with the PROPEL intervention and transition to GAE; however, there would be a risk of contamination as staff administering the GAE would have been trained in PROPEL, which might influence how they treat their patients.^{26 56}

Participants in the PROPEL phase will have one extra hour per week of interaction with the PT and with other participants in the group. It is possible that this extra attention/interaction alone, rather than the content of the PROPEL discussions, will influence the study results. We opted to not add an attention control activity to the GAE phase (e.g., group discussion on a topic unrelated to physical activity) based on feedback from stakeholders. We designed the GAE phase to resemble clinical practice as closely as possible, while still maintaining controls and standardization necessary for a research study. An unrelated discussion group would be contrived for the purpose of the study and would not reflect clinical practice.

1
2 630 This large multi-site trial will determine if a simple clinical intervention, delivered during stroke
3
4 631 rehabilitation, can increase participation in physical activity after discharge. This work addresses
5
6 632 methodological limitations of studies aiming to increase exercise participation post-stroke^{16 17} by: 1)
7
8
9 633 basing the intervention on principles of behaviour modification; 2) using objective measures of
10
11 634 exercise participation; and 3) evaluating long-term self-directed exercise (i.e., 6 months post-
12
13 635 intervention). If the study results are positive, translation of this program into practice has the potential
14
15
16 636 to reduce healthcare costs (by reducing risk of cardiovascular events) and increase independence for
17
18 637 stroke survivors.
19

20 638
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12. REFERENCES

1. Tang A, Sibley KM, Thomas SG, McIlroy WE, Brooks D. Maximal exercise test results in subacute stroke. *Arch Phys Med Rehabil* 2006;87:1100-1105.
2. Brooks D, Tang A, Sibley K, McIlroy WE. Profile of patients at admission into an inpatient stroke rehabilitation program: cardiorespiratory fitness and functional characteristics. *Physiother Can* 2008;60(2):171-179.
3. MacKay-Lyons MJ, Makrides L. Exercise capacity early after stroke. *Arch Phys Med Rehabil* 2002;83:1697-1702.
4. Rimmer JH, Wang E. Aerobic exercise training in stroke survivors. *Top Stroke Rehabil* 2005;12(1):17-30.
5. Tang A, Marzolini S, Oh P, McIlroy WE, Brooks D. Feasibility and effects of adapted cardiac rehabilitation after stroke: a prospective trial. *BMC Neurol* 2010;10:40.
6. Tang A, Sibley KM, Thomas SG, Bayley M, Richardson D, McIlroy WE, et al. Effects of an aerobic exercise program on aerobic capacity, spatiotemporal gait parameters, and functional capacity in subacute stroke. *Neurorehabil Neural Repair* 2009;23:389-397.
7. Stoller O, de Bruin ED, Knols RH, Hunt JJ. Effects of cardiovascular exercise early after stroke: systematic review and meta-analysis. *BMC Neurology* 2012;12:45.
8. Saunders DH, Sanderson M, Brazzelli M, Gerig CA, Mead GE. Physical fitness training for stroke patients. *Cochrane Database Syst Rev* 2013(10):CD003316.
9. Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Mortag Johnson C, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;45:2532-2553.
10. Biasin L, Sage MD, Brunton K, Fraser JE, Mileris R, Howe J, et al. Integrating aerobic training within sub-acute stroke rehabilitation: a feasibility study. *Phys Ther* 2014;94(12):1796-1806.

- 1
2 663 11. Michael KM, Allen JK, Macko RF. Reduced ambulatory activity after stroke: the role of balance,
3
4 664 gait, and cardiovascular fitness. *Arch Phys Med Rehabil* 2005;86:1552-1556.
5
6 665 12. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many
7
8
9 666 steps/day are enough? For older adults and special populations. *Int J Behav Nutr Phys Act*
10
11 667 2011;8:80.
12
13 668 13. Baert I, Feys H, Daly D, Troosters T, Vanlandewijck Y. Are patients 1 year post-stroke active
14
15
16 669 enough to improve their physical health? *Disabil Rehabil* 2012;34(7):574-580.
17
18 670 14. Morris JH, Williams B. Optimising long-term participation in physical activities after stroke:
19
20 671 exploring new ways of working for physiotherapists. *Physiotherapy* 2009;95:227-233.
21
22 672 15. Rosenberg DE, Bombardier CH, Hoffman JM, Belza B. Physical activity among persons aging with
23
24
25 673 mobility disabilities: shaping a research agenda. *J Aging Res* 2011;2011:708510.
26
27 674 16. Jones TM, Dean CM, Hush JM, Dear BF, Titov N. A systematic review of the efficacy of self-
28
29
30 675 management programs for increasing physical activity in community-dwelling adults with
31
32 676 acquired brain injury. *Systematic Reviews* 2015;4:51.
33
34 677 17. Morris JH, MacGillivray S, Mcfarlane S. Interventions to promote long-term participation in
35
36 678 physical activity after stroke: a systematic review of the literature. *Arch Phys Med Rehabil*
37
38
39 679 2014;95:956-967.
40
41 680 18. Kim H, Kim O. The lifestyle modification coaching program for secondary stroke prevention. *J*
42
43 681 *Korean Acad Nurs* 2013;43(3):331-340.
44
45 682 19. Damush TM, Ofner S, Yu Z, Plue L, Nicholas G, Williams LS. Implementation of a stroke self-
46
47
48 683 management program: a randomized controlled pilot study of veterans with stroke. *Transl*
49
50 684 *Behav Med* 2011;1(4):561-572.
51
52
53
54
55
56
57
58
59
60

- 1
2 685 20. Gillham S, Endacott R. Impact of enhanced secondary prevention on health behaviour in patients
3
4 686 following minor stroke and transient ischaemic attack: a randomized controlled trial. *Clin*
5
6 687 *Rehabil* 2010;24:822-830.
- 8
9 688 21. Huijbregts M, Myers A, Streiner D, Teasell R. Implementation, process and preliminary outcomes
10
11 689 evaluation of two community programs for persons with stroke and their care partners. *Top*
12
13 690 *Stroke Rehabil* 2008;15:503-520.
- 15
16 691 22. van der Ploeg HP, Streppel KRM, van der Beek AJ, van der Woude LHV, Vollenbroek-Hutten
17
18 692 MMR, van Harten WH, et al. Successfully improving physical activity behavior after
19
20 693 rehabilitation. *American Journal of Health Promotion* 2007;21(3):153-159.
- 22
23 694 23. Zalewski KR, Dvorak L. Barriers to physical activity between adults with stroke and their care
24
25 695 partners. *Top Stroke Rehabil* 2011;18(Suppl 1):666-675.
- 26
27 696 24. Mansfield A, Knorr S, Poon V, Inness EL, Middleton L, Biasin L, et al. Promoting Optimal
28
29 697 Physical Exercise for Life (PROPEL) - an exercise and self-management program to encourage
30
31 participation in physical activity after discharge from stroke rehabilitation: a feasibility study.
32 698
33
34 699 *Stroke Res Treat* 2016;2016:9476541.
- 35
36 700 25. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. Quantity and
37
38 quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and
39 701
40 neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci*
41 702
42
43 703 *Sports Exerc* 2011;43(7):1334-1359.
- 44
45 704 26. Copas AJ, Lewis JJ, Thompson JA, Davey C, Baio G, Hargreaves JR. Designing a stepped wedge
46
47 trial: three main designs, carry-over effects and randomisation approaches. *Trials* 2015;16:352.
- 48 705
49
50 706 27. Mdege ND, Man M-S, Taylor CA, Torgerson DJ. Systematic review of stepped wedge cluster
51
52 707 randomized trials shows that design is particularly used to evaluate interventions during routine
53
54 implementation. *J Clin Epidemiol* 2011;64:936-948.
- 55 708
56
57
58
59
60

- 1
2 709 28. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised
3
4 710 trial: rationale, design, analysis, and reporting. *Br Med J* 2015;351:h391.
5
6 711 29. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14(5):377-381.
7
8
9 712 30. Prochaska JO, Di Clemente CC. Transtheoretical therapy: toward a more integrative model of
10
11 713 change. *Psychother: Theor Res* 1982;19(3):276-288.
12
13 714 31. Bandura A. Health promotion by social cognitive means. *Health Educ Behav* 2004;31(2):143-164.
14
15
16 715 32. Bandura A. *Self efficacy. The exercise of control*. New York: W.H. Freeman, 1997.
17
18 716 33. Kinne S, Patrick DL, Maher EJ. Correlates of exercise maintenance among people with mobility
19
20 717 impairments. *Disabil Rehabil* 1999;21(1):15-22.
21
22
23 718 34. Reed M, Harrington A, Duggan A, Wood VA. Meeting stroke survivors perceived needs: a
24
25 719 qualitative study of community-based exercise and education scheme. *Clin Rehabil*
26
27 720 2010;24(1):16-25.
28
29
30 721 35. Resnick B, Michael K, Shaughnessy M, Nahm ES, Kobunek S, Sorkin J, et al. Inflated perceptions
31
32 722 of physical activity after stroke: pairing self-report with physiologic measures. *J Phys Act*
33
34 723 *Health* 2008;5(2):308-318.
35
36
37 724 36. Klassen TD, Simpson LA, Lim SB, Louie DR, Parappilly B, Sakakibara BM, et al. "Stepping up"
38
39 725 activity poststroke: ankle-positioned accelerometer can accurately record steps during slow
40
41 726 walking. *Phys Ther* 2016;96(3):355-360.
42
43
44 727 37. Washburn RA, Zhu W, McAuley E, Frogley M, Figoni SF. The Physical Activity Scale for
45
46 728 Individuals with Physical Disabilities: development and evaluation. *Arch Phys Med Rehabil*
47
48 729 2002;83:193-200.
49
50 730 38. van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Vollenbroek-Hutten M, van
51
52 731 Mechelen W. The Physical Activity Scale for Individuals with Physical Disabilities: test-retest
53
54
55 732 reliability and comparison with an accelerometer. *J Phys Act Health* 2007;4(1):96-100.
56
57
58
59
60

- 1
2 733 39. Shaughnessy M, Resnick BM, Macko RF. Reliability and validity testing of the Short Self-Efficacy
3
4 734 and Outcome Expectation for Exercise Scales in stroke survivors. *J Stroke Cerebrovasc Dis*
5
6 735 2004;13(5):214-219.
7
8
9 736 40. Barriers to Being Active Quiz: Centers for Disease Control and Prevention.
10
11 737 41. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease
12
13 738 Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion,
14
15 739 Division of Nutrition and Physical Activity. *Promoting physical activity: a guide for community*
16
17 740 *action*. Champaign, Illinois: Human Kinetics, 1999.
18
19
20 741 42. Sawchuck CN, Russo JE, Bogart A, Charles S, Goldberg J, Forquera R, et al. Barriers and
21
22 742 facilitators to walking and physical activity among American Indian elders. *Prev Chronic Dis*
23
24 743 2011;8(3):A63.
25
26
27 744 43. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. *Arch Neurol*
28
29 745 1989;46(6):660-662.
30
31
32 746 44. Gowland C, Stratford P, Ward M, Moreland J, Torresin W, Van Hullenaar S, et al. Measuring
33
34 747 physical impairment and disability with the Chedoke-McMaster Stroke Assessment. *Stroke*
35
36 748 1993;24:58-63.
37
38
39 749 45. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Colin I, et al. The Montreal
40
41 750 cognitive assessment (MoCA): a brief screening tool for mild cognitive impairment. *J Am*
42
43 751 *Geriatr Soc* 2005;53:695-699.
44
45
46 752 46. Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;5:603-612.
47
48 753 47. Raina P, Wolfson C, Kirkland S. Canadian Longitudinal Study on Aging (CLSA) Protocol, 2013.
49
50 754 48. Schmidt ME, Slanger T, Chang-Claude J, Wahrendorf J, Steindorf K. Evaluation of a short
51
52 755 retrospective questionnaire for physical activity in women. *Eur J Epidemiol* 2006;21:575-585.
53
54
55
56
57
58
59
60

- 1
2 756 49. Brown C, Fraser JE, Inness EL, Wong J, Middleton LE, Poon V, et al. Does participation in
3
4 757 standardized aerobic fitness training during inpatient stroke rehabilitation promote engagement
5
6 758 in aerobic exercise after discharge? A cohort study. *Top Stroke Rehabil* 2014;21(Suppl 1):S42-
7
8
9 759 51.
- 10
11 760 50. Donner A, Klar N. *Design and analysis of cluster randomized trials in health research*. London:
12
13 761 Arnold, 2000.
- 14
15
16 762 51. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for
17
18 763 improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;357:1191-
19
20 764 1194.
- 21
22
23 765 52. Davey C, Hargreaves J, Thompson JA, Copas AJ, Beard E, Lewis JJ, et al. Analysis and reporting
24
25 766 of stepped wedge randomised controlled trials: synthesis and critical appraisal of published
26
27 767 studies, 2010 to 2014. *Trials* 2015;16:358.
- 28
29
30 768 53. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, et al. Canadian stroke best
31
32 769 practice recommendations: stroke rehabilitation practice guidelines, update 2015. *Int J Stroke*
33
34 770 2016;11(4):459-484.
- 35
36
37 771 54. MacKay-Lyons M, Macko R, Eng J, Billinger S, Hafer-Macko C, Suskin N, et al. Aerobic exercise
38
39 772 recommendations to optimize best practices in care after stroke, 2012.
- 40
41 773 55. Hargreaves JR, Prost A, Fielding KL, Copas AJ. How important is randomisation in a stepped
42
43 774 wedge trial? *Trials* 2015;16:359.
- 44
45
46 775 56. Beard E, Lewis JJ, Copas A, Davey C, Osrin D, Baio G, et al. Stepped wedge randomised
47
48 776 controlled trials: systematic review of studies published between 2010 and 2014. *Trials*
49
50 777 2015;16(353).
- 51
52
53 778
54
55 779

1
2 780 **13. TABLES**

3
4 781 **Table 1: Overview of data collection time points.**

	Study enrolment	1-month post-discharge	4-months post-discharge	6-months post-discharge
<i>Cohort descriptors</i>				
Chart review form	RA-CR			
NIH-SS	RA-P			
CMSA	RA/PT-CR/P			
MOCA	RA-P			
Baseline questionnaire	RA-P			
6-month follow-up questionnaire				RA-P
Schmidt questionnaire	RA-P			
<i>Primary outcomes</i>				
FitBit activity monitoring*		RA-P	RA-P	RA-P
FitBit heart rate data*		RA-P	RA-P	RA-P
PASIPD**		RA-P	RA-P	RA-P
<i>Secondary outcomes</i>				
SSEE	RA-P			
SOEE	RA-P			
BBAQ		RA-P		

29 782 Outcomes: BBAQ=Barriers to Being Active Quiz; CMSA=Chedoke-McMaster Stroke Assessment; MOCA=Montreal
30 783 Cognitive Assessment; NIH-SS=National Institutes of Health Stroke Scale; PASIPD=Physical Activity Scale for
31 784 Individuals with Physical Disabilities; SOEE=Short Outcome Expectations for Exercise scale; SSEE=Short Self-Efficacy
32 785 for Exercise scale.

33 786 Data collection: PT-CR=data collected by the physiotherapist by chart review; PT-P=data collected by the physiotherapist
34 787 directly from the participant; RA-CR=data collected by the research assistant from chart review; RA-P=data collected by
35 788 research assistant directly from the participant.

36 789 *Activity and heart rate monitoring for 7 days continuously

37 790 **PASIPD questionnaire should be done at the end of the 7-day activity/heart rate monitoring period.

38 791

39

40 792

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

14. FIGURE CAPTIONS

Figure 1: Intervention allocation schedule. G1, G2 etc. are the 6-week long group aerobic exercise (GAE) or PROPEL groups. Each site should be able to complete 8 groups per year; however, only 7 groups will be completed in 2017 to allow for additional time at the start of the year to obtain research ethics approval, inter-institutional agreements, and pilot implementation at all sites (see also Figure 3). ‘0’ indicates that the site will complete GAE in that time period, whereas ‘1’ indicates that they will complete PROPEL. A simple randomization procedure will be used to determine the time at which each site transitions from GAE to PROPEL. Sites will be allocated in order by drawing names from a hat; e.g., the 1st site to be drawn will be Site A, the 2nd will be Site B, etc.

Figure 2: Hypothetical timeline for one participant. The exact timing of in- and out-patient rehabilitation will vary for each participant. The sub-maximal aerobic capacity test is completed during in-patient rehabilitation. After this point the participant could participate in individual or open-group aerobic exercise during in- and out-patient rehabilitation (while waiting to be enrolled in the study intervention). The closed-group study intervention (group aerobic exercise (GAE) only or PROPEL) will likely start during out-patient rehabilitation, though some patients may start during in-patient rehabilitation. The participant will be enrolled in the study at the end of the study intervention, at which point cohort descriptors, the Short Self-Efficacy for Exercise (SSEE) scale, and the Short Outcome Expectations for Exercise (SOEE) scale will be collected. Activity monitoring will be conducted for 7 days continuously at three time points: 1) one month; 2) 4 months; 3) and 6 months after the end of the study intervention. The Barriers to Being Active Quiz (BBAQ) will be conducted at the 1-month post-intervention time point.

	2017							2018							
	G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12	G13	G14	G15
Site A	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Site B	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1
Site C	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1
Site D	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
Site E	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
Site F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Figure 1: Intervention allocation schedule. G1, G2 etc. are the 6-week long group aerobic exercise (GAE) or PROPEL groups. Each site should be able to complete 8 groups per year; however, only 7 groups will be completed in 2017 to allow for additional time at the start of the year to obtain research ethics approval, inter-institutional agreements, and pilot implementation at all sites (see also Figure 3). '0' indicates that the site will complete GAE in that time period, whereas '1' indicates that they will complete PROPEL. A simple randomization procedure will be used to determine the time at which each site transitions from GAE to PROPEL. Sites will be allocated in order by drawing names from a hat; e.g., the 1st site to be drawn will be Site A, the 2nd will be Site B, etc.




Figure 2: Hypothetical timeline for one participant. The exact timing of in- and out-patient rehabilitation will vary for each participant. The sub-maximal aerobic capacity test is completed during in-patient rehabilitation. After this point the participant could participate in individual or open-group aerobic exercise during in- and out-patient rehabilitation (while waiting to be enrolled in the study intervention). The closed-group study intervention (group aerobic exercise (GAE) only or PROPEL) will likely start during out-patient rehabilitation, though some patients may start during in-patient rehabilitation. The participant will be enrolled in the study at the end of the study intervention, at which point cohort descriptors, the Short Self-Efficacy for Exercise (SSEE) scale, and the Short Outcome Expectations for Exercise (SOEE) scale will be collected. Activity monitoring will be conducted for 7 days continuously at three time points: 1) one month; 2) 4 months; 3) and 6 months after the end of the study intervention. The Barriers to Being Active Quiz (BBAQ) will be conducted at the 1-month post-intervention time point.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3-5
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1-2
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	1-2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	8-9
	6b	Explanation for choice of comparators	8
Objectives	7	Specific objectives or hypotheses	9
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	9-10

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	10
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	11-12
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12-14
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	12-14
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14-17
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 2

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	18
6				
7				
8	Methods: Assignment of interventions (for controlled trials)			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	18-19
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	18-19
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	18-19
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	19
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	19-20
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	20
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	20-21
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	21
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	21
13				
14				
15	Methods: Monitoring			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	22
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	22-24
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	22-24
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	24
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	24-25
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	25
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	25-26
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	26
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	26
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	26
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	26-27
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	27
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	27
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40

41
 42
 43
 44
 45
 46
 47

CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY

Title of the study: Promoting Optimal Physical Exercise for Life (PROPEL) – aerobic exercise and self-management early after stroke to increase daily physical activity: a randomized trial

Principal investigator

Avril Mansfield, PhD
Scientist, Toronto Rehabilitation Institute – UHN
Phone: 416-597-3422 ext. 7831

Contact Information

Anthony Aqui, MSc
Clinical Research Analyst, Toronto Rehabilitation Institute – UHN
Phone: 416-597-3422 ext 7826

Funding

This study is funded by the Canadian Institutes of Health Research

Introduction

You are being asked to take part in a research study. Please read the information about the study presented in this form. The form includes details on study's risks and benefits that you should know before you decide if you would like to take part. You should take as much time as you need to make your decision. You should ask the study staff to explain anything that you do not understand and make sure that all of your questions have been answered before signing this consent form. Before you make your decision, feel free to talk about this study with anyone you wish including your friends, family, and family doctor. Participation in this study is voluntary.

Background and purpose

Research shows that physical exercise is good for people with stroke. However, many people with stroke do not perform enough exercise. The purpose of this study is to see if a fitness program delivered during rehabilitation helps people with stroke to be more physically active *after* leaving the rehabilitation hospital. You are being asked to participate in this study because you completed this fitness program during your rehabilitation stay at the Toronto Rehabilitation Institute.

Study visits and procedures

If you agree to participate in this study, we will measure how much physical activity you do over the 6-months after you finish out-patient rehabilitation at the Toronto Rehabilitation Institute. We will do this by asking you to wear an activity monitor on your wrist for three 1-week periods: 1-month, 4-months, and 6-months after you finish rehabilitation. The activity monitor looks like a watch and counts how many steps you take during the day. It also measures how fast your heart is beating. We will mail the activity monitor to you and ask you to return it in a postage-paid envelope. You can remove the activity monitor before you go to bed. You should remove the activity monitor before bathing/showing, if you go swimming, if it becomes uncomfortable to wear, or if you are requested to do so for any medical care.

Wrist activity monitor



Time	Time commitment	Tests and procedures	Location
Around the time of discharge from the hospital	~30 minutes	Tests of leg function, and memory Questionnaires about previous exercise habits and how you feel about exercise	Toronto Rehab
1-month post-discharge	~30 minutes	Activity monitoring Questionnaire about your physical activities	Your home (telephone call)
4-months post-discharge	~30 minutes		
6-months post-discharge	~30 minutes		

Some types of exercise might not be recorded by the activity monitor; for example, if you go swimming or do exercises where you don't walk around a lot (like seated exercises at home). For this reason, we will also ask you to complete a questionnaire about your physical activities. A research assistant will call you to ask you to complete this questionnaire three times: 1-month, 4-months, and 6-months after you finish rehabilitation. The questionnaire will take about 10-15 minutes to complete. At these time points, the research assistant will also ask you if there have been any changes to your health since he last spoke to you.

With your permission we will obtain information from your clinical chart such as your age, gender, height, weight, information about your stroke and the effects it has had

1 on you, and information about your medical conditions and medications. You do not
2 have to do anything extra for this chart review. Before you are discharged from the
3 rehabilitation hospital, we will also measure your leg function, and you memory and
4 will ask you some questions about yourself, your previous exercise habits, and how
5 you feel about exercise. It will take about 30 minutes to perform these measures; we
6 will schedule the testing at a time that is convenient for you. This information is
7 necessary in order to describe the group of people who are participating in this
8 study.
9
10
11
12

13 **Potential harms, discomforts and inconveniences**

14 There is some extra time involved with participating in this study. You might find this
15 a burden. We think it will take about 3 hours to complete all of the parts of this study.
16 This time commitment will be spread out over 6 months. You might find that it is a
17 burden to wear the activity monitor every day for three 1-week periods or to mail the
18 activity monitors back to us.
19
20
21
22

23 There is a small chance that you will feel uncomfortable answering some of the
24 questions related to the study. You are free to choose not to answer any question.
25
26

27 There is a small chance you will develop a skin irritation from wearing the activity
28 monitor. Removing the activity monitor at night might help to prevent this from
29 happening. If you do develop a skin irritation on your wrist, remove the activity
30 monitor and call the research assistant to let him know.
31
32
33

34 **Potential benefits**

35 You will not directly benefit from being in this study. Information learned from this
36 study may give us more information about how to increase participation in exercise
37 in people with stroke after they leave rehabilitation. These results could be used to
38 benefit other people with stroke in the future.
39
40
41

42 **Reminders and responsibilities**

43 It is important to remember the following things during the study:

- 44 • Tell the study staff your health history and medications as accurately as
45 possible. This will help to prevent any harm to you.
- 46 • Ask the study staff about anything that worries you.
- 47 • Tell the study staff if anything about your health has changed.
- 48 • Wear the activity monitors every day for a week on three different
49 occasions, and return them to us in the postage-paid envelope.
50
51
52
53
54
55
56
57
58
59
60

Confidentiality

Personal Health Information

If you agree to join this study, the research team will collect your personal health information. Personal health information is any information that could identify you and includes your:

- name,
- age,
- telephone number, and
- existing medical records, including types, dates and results of medical tests or procedures.

Representatives of the University Health Network Research Ethics Board may look at the study records and at your personal health information to check that the information collected for the study is correct and to make sure the study is following proper laws and guidelines.

The research team will keep any personal health information about you in a secure and confidential location for 10 years. A list linking your study number with your name will be kept by the research team in a secure place, separate from your study file.

Study information that does not identify you

This is a multi-site study; Sunnybrook Research Institute is the lead site for this study. Some study information will be sent outside of the hospital to Sunnybrook Research Institute. Any information that is sent out of the hospital will have a code and will not show your name or address, or any information that directly identifies you.

All information collected during this study, including your personal health information, will be kept confidential. Information from the activity monitors will be stored on the manufacturer's web servers; however, this information will be completely anonymous and will not be associated with any information that could identify you. Your personal health information will not be shared with anyone outside of the study unless required by law. You will not be named in any reports, publications, or presentations that may come from this study.

Voluntary participation

You are encouraged to ask any questions that you may have about this study. If you do not wish to participate in this study, it will not affect any treatment that you receive at Toronto Rehabilitation Institute – UHN, either now or in the future.

1
2 Your participation in this study is voluntary. You may decide not to be in this study,
3 or to be in the study now and then change your mind later. We will give you any new
4 information that is learned during the study that might affect your decision to stay in
5 the study.
6
7

8 **Withdrawal from study**

9
10 If you chose to participate initially but wish to withdraw at a later date, for any
11 reason, it will not affect the current or future care that you receive at Toronto
12 Rehabilitation Institute – UHN. If you decide to withdraw from the study, the
13 information that was collected before you leave the study will still be used in order to
14 help answer the research question. No new information will be collected without
15 your permission.
16
17
18

19 **Costs and reimbursement**

20 Participation in this study will not involve any additional costs to you. You will
21 receive a \$30 gift card after completing all parts of the study as a token of our
22 appreciation for your participation.
23
24
25

26 **Rights as a participant**

27 If you are harmed as a direct result of taking part in this study, all necessary
28 medical treatment will be made available to you at no cost.
29
30

31 By signing this form you do not give up any of your legal rights against the
32 investigators, sponsor or involved institutions for compensation, nor does this
33 form relieve the investigators, sponsor or involved institutions of their legal and
34 professional responsibilities.
35
36
37

38 **Conflict of interest**

39 Researchers have an interest in completing this study. Their interests should not
40 influence your decision to participate in this study.
41
42
43

44 **Questions about the study**

45 If you have any questions, concerns or would like to speak to the study team for
46 any reason, please call the Principal Investigator Avril Mansfield at 416-597-3422
47 extension 7831. **If you have any questions about your rights as a research**
48 **participant or have concerns about this study, call the Chair of the**
49 **University Health Network Research Ethics Board (UHN REB) or the**
50 **Research Ethics office number at 416-581-7849.** The REB is a group of people
51 who oversee the ethical conduct of research studies. The UHN REB is not part of
52 the study team. Everything that you discuss will be kept confidential.
53 You will be given a copy of this form.
54
55
56
57
58
59

Consent

This study has been explained to me and any questions I had have been answered. I know that I may leave the study at any time. I agree to the use of my information as described in this form. I agree to take part in this study.

In some cases when we are unable to contact you directly, may we leave a voice message (if applicable)? No personal health information will be included in the voice message.

Yes _____(initials) No _____(initials)

If we have been unable to contact you after repeated attempts by telephone or mail, may we contact a friend or family member? We will ask for your friend or family member's contact information in a separate document. We will not share any of your personal health information with your friend or family member.

Yes _____(initials) No _____(initials)

Study participant's name Signature Date

My signature means that I have explained the study to the participant named above. I have answered all questions.

Name of person obtaining consent Signature Date

Was the participant assisted during the consent process? YES NO

If **YES**, please check the relevant box and complete the signature space below:

The consent form was read to the participant. The person signing below attests that the study as set out in this form was accurately explained to, and has had any questions answered.

Name of witness Signature Date

Relationship to participant